≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Benign neoplasm: Other parts of oropharynx

DOID Endpoint Browser PheWeb

CD2_BENIGN_OROPHA_OTHER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D10.5&
  • Hospital discharge: ICD-9 — 2106
  • Hospital discharge: ICD-8 — 2106
  • Cause of death: ICD-10 — D10.5&
  • Cause of death: ICD-9 — 2106
  • Cause of death: ICD-8 — 2106

2 out of 7 registries used, show all original rules.

348

4. Check minimum number of events

None

348

5. Include endpoints

None

348

6. Filter based on genotype QC (FinnGen only)

334

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D10
Name in latin
Neoplasma benignum oropharyngis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2025 1071 939
Only index persons 1865 1002 863
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.03
Only index persons 0.04 0.04 0.03
Median age at first event (years)
Whole population 51.53 52.28 50.52
Only index persons 50.66 51.48 49.72

-FinnGen-

Key figures

All Female Male
Number of individuals 334 194 140
Unadjusted period prevalence (%) 0.07 0.07 0.06
Median age at first event (years) 54.33 50.80 59.23

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
348
Matched controls
3480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D10.5
ICD-10 Finland
Benign neoplasm: Other parts of oropharynx
+∞
307.7
331
*
ENA10
NOMESCO Finland
Biopsy of pharynx
142.0
47.1
49
*
UJC01
NOMESCO Finland
Scopy of lower throat
27.9
24.5
33
13
EHA10
NOMESCO Finland
Biopsy of palate
64.2
21.2
24
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
4.5
17.0
45
112
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
19.1
16.7
25
14
ENB00
NOMESCO Finland
Excision or exploration of lesion of pharynx
167.2
15.6
16
*
K13.79
ICD-10 Finland
Change in the oral mucosa UNS
6.5
14.9
25
41
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
20.2
14.4
21
11
EHB00
NOMESCO Finland
Excision of lesion of palate
33.4
12.7
16
5
R07.0
ICD-10 Finland
Pain in throat
3.6
12.4
43
130
EJA10
NOMESCO Finland
Biopsy of tongue or floor of mouth
11.1
11.9
22
21
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.7
11.0
37
109
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
20.8
9.9
14
7
UDH02
NOMESCO Finland
Rhinopharyngoscopy
3.2
9.4
40
137
G47.3
ICD-10 Finland
Sleep apnoea
2.2
9.2
101
551
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
9.4
9.1
18
20
D10.9
ICD-10 Finland
Benign neoplasm: Pharynx, unspecified
51.3
8.7
10
*
WX402
NOMESCO Finland
General anaesthesia
2.1
8.6
96
524
R21
ICPC
Throat symptom/complaint
2.2
8.6
94
509
J39.2
ICD-10 Finland
Other diseases of pharynx
10.4
8.1
15
15
WZC00
NOMESCO Finland
Treatment plan or consultation
1.9
8.0
146
947
JDB10
NOMESCO Finland
Percutaneous gastrostomy
11.2
7.9
14
13
D37.08
ICD-10 Finland
Tumor of uncertain or unknown nature in other part of lip, oral cavity and pharynx
46.0
7.7
9
*
WF002
NOMESCO Finland
Radical radiotherapy
3.5
7.7
27
82
GBB00
NOMESCO Finland
Tracheostomy
12.2
7.6
13
11
C01
ICD-10 Finland
Malignant neoplasm of base of tongue
81.8
7.4
8
*
21068
ICD-8 Finland
Benign neoplasm of buccal cavity and pharynx, Other parts of oropharynx
+∞
7.3
7
*
2106A
ICD-9 Finland
Benign neoplasm of lip, oral cavity and pharynx, Other parts of oropharynx
+∞
7.3
7
*
J35.0
ICD-10 Finland
Chronic tonsillitis
3.4
7.3
27
85
EMA10
NOMESCO Finland
Biopsy of tonsil
20.5
7.2
10
5
ZXE00
NOMESCO Finland
One hour or less
1.9
7.0
142
944
130
Kela drug reimbursment
Malignant tumour
2.6
7.0
41
168
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
7.8
7.0
15
20
J38.1
ICD-10 Finland
Polyp of vocal cord and larynx
14.1
6.9
11
8
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
14.1
6.9
11
8
EMB10
NOMESCO Finland
Tonsillectomy
3.2
6.8
28
94
D10.39
ICD-10 Finland
Benign tumor in other or unspecified part of oral cavity UNS
23.0
6.7
9
*
EMB00
NOMESCO Finland
Excision of lesion of tonsil or adenoids
71.1
6.4
7
*
Z01.2
ICD-10 Finland
Dental examination
1.8
6.3
172
1240
ZXD10
NOMESCO Finland
Scheduled procedure
1.8
6.1
132
887

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Otolaryngology
4 [38004449]
4.9e-01
1.4e+00
3.1e+00
1.0e+50
4.5e+00
3.2e+00
1.4e+00
cases:16.03%
controls:10.48%
cases:14.58%
controls:3.85%
cases:13.99%
controls:0.70%
cases:94.17%
controls:0.00%
cases:37.61%
controls:0.64%
cases:42.51%
controls:3.04%
cases:33.45%
controls:10.57%
55
359
288
3066
50
132
293
3293
48
24
295
3401
323
0
20
3425
129
22
214
3400
142
102
192
3253
99
319
197
2699
Outpatient Visit
OP [9202]
2.7e-01
5.1e-01
7.9e-01
5.5e+00
1.5e+00
9.4e-01
6.8e-01
cases:73.47%
controls:67.82%
cases:60.35%
controls:47.68%
cases:22.45%
controls:11.56%
cases:59.77%
controls:0.58%
cases:37.32%
controls:11.31%
cases:70.66%
controls:48.44%
cases:86.82%
controls:76.94%
252
2323
91
1102
207
1633
136
1792
77
396
266
3029
205
20
138
3405
128
387
215
3035
236
1625
98
1730
257
2322
39
696
Tissue Pathology biopsy report
66121-5 [40768804]
2.1e-01
4.1e-01
2.4e+00
1.0e+50
2.4e+00
1.6e+00
7.0e-01
cases:9.62%
controls:7.94%
cases:4.37%
controls:2.95%
cases:3.21%
controls:0.29%
cases:14.87%
controls:0.00%
cases:4.66%
controls:0.44%
cases:10.78%
controls:2.41%
cases:16.55%
controls:8.98%
33
272
310
3153
15
101
328
3324
11
10
332
3415
51
0
292
3425
16
15
327
3407
36
81
298
3274
49
271
247
2747
Throat symptom/complaint
R21 [2002000891]
8.8e-01
2.2e+00
3.0e+00
—
—
—
9.3e-01
cases:6.71%
controls:2.89%
cases:6.12%
controls:0.73%
cases:3.79%
controls:0.20%
—
—
—
—
—
—
cases:8.11%
controls:3.38%
23
99
320
3326
21
25
322
3400
13
7
330
3418
—
—
—
24
102
272
2916
One hour or less
ZXE00 [2001311394]
6.6e-01
2.6e-01
—
1.0e+50
3.3e+00
1.7e+00
8.0e-01
cases:9.91%
controls:5.37%
cases:2.33%
controls:1.81%
—
—
cases:2.62%
controls:0.00%
cases:4.66%
controls:0.18%
cases:8.98%
controls:1.79%
cases:8.45%
controls:3.98%
34
184
309
3241
8
62
335
3363
—
9
0
334
3425
16
6
327
3416
30
60
304
3295
25
120
271
2898
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.6e-01
5.2e-01
1.3e+00
2.3e+00
9.6e-01
6.4e-01
4.9e-01
cases:31.49%
controls:26.07%
cases:25.66%
controls:17.08%
cases:10.50%
controls:3.24%
cases:1.75%
controls:0.18%
cases:7.87%
controls:3.16%
cases:29.94%
controls:18.36%
cases:50.00%
controls:38.10%
108
893
235
2532
88
585
255
2840
36
111
307
3314
6
6
337
3419
27
108
316
3314
100
616
234
2739
148
1150
148
1868
General anesthesia, balanced
WX408 [2001310808]
3.3e-01
4.8e-01
—
1.0e+50
2.8e+00
2.0e+00
1.2e+00
cases:5.83%
controls:4.26%
cases:1.46%
controls:0.91%
—
—
cases:2.92%
controls:0.00%
cases:2.92%
controls:0.18%
cases:4.79%
controls:0.69%
cases:6.08%
controls:1.86%
20
146
323
3279
5
31
338
3394
—
10
0
333
3425
10
6
333
3416
16
23
318
3332
18
56
278
2962
Scheduled procedure
ZXD10 [2001311387]
4.1e-01
3.6e-01
—
1.0e+50
3.5e+00
1.5e+00
1.0e+00
cases:9.62%
controls:6.60%
cases:2.33%
controls:1.64%
—
—
cases:2.04%
controls:0.00%
cases:4.66%
controls:0.15%
cases:6.89%
controls:1.67%
cases:8.45%
controls:3.28%
33
226
310
3199
8
56
335
3369
—
7
0
336
3425
16
5
327
3417
23
56
311
3299
25
99
271
2919
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
7.6e-02
3.5e-01
1.1e+00
2.9e+00
1.0e+00
4.2e-01
3.8e-01
cases:30.61%
controls:29.02%
cases:28.57%
controls:21.99%
cases:10.20%
controls:3.65%
cases:2.62%
controls:0.15%
cases:9.62%
controls:3.59%
cases:33.53%
controls:24.83%
cases:53.72%
controls:44.20%
105
994
238
2431
98
753
245
2672
35
125
308
3300
9
5
334
3420
33
123
310
3299
112
833
222
2522
159
1334
137
1684
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
5.6e-02
3.9e-01
1.1e+00
2.8e+00
1.1e+00
4.5e-01
4.1e-01
cases:30.03%
controls:28.88%
cases:28.86%
controls:21.61%
cases:10.20%
controls:3.53%
cases:2.33%
controls:0.15%
cases:9.62%
controls:3.51%
cases:33.53%
controls:24.29%
cases:53.72%
controls:43.61%
103
989
240
2436
99
740
244
2685
35
121
308
3304
8
5
335
3420
33
120
310
3302
112
815
222
2540
159
1316
137
1702
Laboratory Visit
OMOP4822461 [32036]
9.3e-02
2.4e-01
9.4e-01
3.6e+00
8.0e-01
1.9e-01
1.8e-01
cases:41.69%
controls:39.45%
cases:43.15%
controls:37.34%
cases:23.91%
controls:10.98%
cases:20.41%
controls:0.67%
cases:21.87%
controls:11.16%
cases:45.21%
controls:40.57%
cases:61.82%
controls:57.42%
143
1351
200
2074
148
1279
195
2146
82
376
261
3049
70
23
273
3402
75
382
268
3040
151
1361
183
1994
183
1733
113
1285
Case Management Agency
251B00000X [38004193]
5.1e-02
1.6e-01
9.2e-01
3.5e+00
7.5e-01
1.3e-01
1.2e-01
cases:62.39%
controls:61.20%
cases:58.31%
controls:54.48%
cases:38.78%
controls:20.23%
cases:30.61%
controls:1.26%
cases:36.73%
controls:21.54%
cases:60.78%
controls:57.59%
cases:75.00%
controls:72.73%
214
2096
129
1329
200
1866
143
1559
133
693
210
2732
105
43
238
3382
126
737
217
2685
203
1932
131
1423
222
2195
74
823
Medical doctor
Z2221 [2001311556]
8.0e-01
1.3e+00
—
1.0e+50
—
2.0e+00
1.1e+00
cases:9.33%
controls:4.41%
cases:3.50%
controls:0.99%
—
—
cases:4.37%
controls:0.00%
—
—
cases:6.59%
controls:0.95%
cases:6.42%
controls:2.19%
32
151
311
3274
12
34
331
3391
—
15
0
328
3425
—
22
32
312
3323
19
66
277
2952
Supplier / Service Provider
OMOP5117446 [33004]
-1.2e+00
-8.9e-01
—
—
—
3.2e+00
3.2e+00
cases:10.79%
controls:29.14%
cases:3.50%
controls:8.15%
—
—
—
—
—
—
cases:10.18%
controls:0.48%
cases:19.93%
controls:1.03%
37
998
306
2427
12
279
331
3146
—
—
—
34
16
300
3339
59
31
237
2987
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.4e-02
3.3e-01
1.0e+00
2.9e+00
8.9e-01
3.2e-01
3.0e-01
cases:32.65%
controls:31.91%
cases:32.94%
controls:26.01%
cases:13.12%
controls:5.08%
cases:3.50%
controls:0.20%
cases:11.08%
controls:4.85%
cases:35.63%
controls:28.58%
cases:55.74%
controls:48.31%
112
1093
231
2332
113
891
230
2534
45
174
298
3251
12
7
331
3418
38
166
305
3256
119
959
215
2396
165
1458
131
1560
Emergency Room Visit
ER [9203]
1.9e-01
5.4e-01
1.6e+00
1.0e+50
1.4e+00
6.8e-01
4.6e-01
cases:35.86%
controls:31.59%
cases:17.49%
controls:11.01%
cases:6.12%
controls:1.31%
cases:2.62%
controls:0.00%
cases:4.96%
controls:1.32%
cases:18.86%
controls:10.49%
cases:36.15%
controls:26.38%
123
1082
220
2343
60
377
283
3048
21
45
322
3380
9
0
334
3425
17
45
326
3377
63
352
271
3003
107
796
189
2222
Oral Surgery
19 [38004464]
1.0e+00
—
—
—
1.0e+50
3.1e+00
1.5e+00
cases:2.62%
controls:0.96%
—
—
—
—
—
—
cases:2.04%
controls:0.00%
cases:3.89%
controls:0.18%
cases:3.38%
controls:0.76%
9
33
334
3392
—
—
—
7
0
336
3422
13
6
321
3349
10
23
286
2995
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.4e-01
3.0e-01
1.0e+00
2.8e+00
7.4e-01
2.6e-01
2.4e-01
cases:38.19%
controls:34.95%
cases:35.86%
controls:29.28%
cases:14.29%
controls:5.75%
cases:3.21%
controls:0.20%
cases:11.95%
controls:6.11%
cases:38.02%
controls:32.01%
cases:58.78%
controls:52.85%
131
1197
212
2228
123
1003
220
2422
49
197
294
3228
11
7
332
3418
41
209
302
3213
127
1074
207
2281
174
1595
122
1423
MCH [Entitic mass]
28539-5 [3035941]
1.4e-01
2.9e-01
1.0e+00
2.8e+00
7.2e-01
2.7e-01
2.4e-01
cases:38.19%
controls:34.86%
cases:35.57%
controls:29.17%
cases:14.29%
controls:5.75%
cases:3.21%
controls:0.20%
cases:11.66%
controls:6.02%
cases:38.02%
controls:31.89%
cases:58.78%
controls:52.78%
131
1194
212
2231
122
999
221
2426
49
197
294
3228
11
7
332
3418
40
206
303
3216
127
1070
207
2285
174
1593
122
1425
Platelets [#/volume] in Blood
26515-7 [3007461]
1.5e-01
3.0e-01
1.0e+00
2.8e+00
7.2e-01
2.7e-01
2.5e-01
cases:38.19%
controls:34.74%
cases:35.57%
controls:29.11%
cases:14.29%
controls:5.75%
cases:3.21%
controls:0.20%
cases:11.66%
controls:6.02%
cases:38.02%
controls:31.80%
cases:58.78%
controls:52.72%
131
1190
212
2235
122
997
221
2428
49
197
294
3228
11
7
332
3418
40
206
303
3216
127
1067
207
2288
174
1591
122
1427
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.4e-01
2.9e-01
1.0e+00
2.8e+00
7.2e-01
2.7e-01
2.4e-01
cases:38.19%
controls:34.92%
cases:35.57%
controls:29.23%
cases:14.29%
controls:5.75%
cases:3.21%
controls:0.20%
cases:11.66%
controls:6.05%
cases:38.02%
controls:31.92%
cases:58.78%
controls:52.85%
131
1196
212
2229
122
1001
221
2424
49
197
294
3228
11
7
332
3418
40
207
303
3215
127
1071
207
2284
174
1595
122
1423
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.4e-01
2.9e-01
1.0e+00
2.8e+00
7.1e-01
2.8e-01
2.4e-01
cases:38.19%
controls:34.95%
cases:35.57%
controls:29.23%
cases:14.29%
controls:5.75%
cases:3.21%
controls:0.20%
cases:11.66%
controls:6.08%
cases:38.32%
controls:31.98%
cases:58.78%
controls:52.85%
131
1197
212
2228
122
1001
221
2424
49
197
294
3228
11
7
332
3418
40
208
303
3214
128
1073
206
2282
174
1595
122
1423
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.4e-01
2.9e-01
1.0e+00
2.8e+00
7.1e-01
2.7e-01
2.4e-01
cases:38.19%
controls:34.92%
cases:35.57%
controls:29.23%
cases:14.29%
controls:5.75%
cases:3.21%
controls:0.20%
cases:11.66%
controls:6.08%
cases:38.02%
controls:31.98%
cases:58.78%
controls:52.85%
131
1196
212
2229
122
1001
221
2424
49
197
294
3228
11
7
332
3418
40
208
303
3214
127
1073
207
2282
174
1595
122
1423
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.4e-01
2.9e-01
1.0e+00
2.8e+00
7.1e-01
2.7e-01
2.4e-01
cases:38.19%
controls:34.92%
cases:35.57%
controls:29.17%
cases:14.29%
controls:5.75%
cases:3.21%
controls:0.20%
cases:11.66%
controls:6.08%
cases:38.02%
controls:31.92%
cases:58.78%
controls:52.78%
131
1196
212
2229
122
999
221
2426
49
197
294
3228
11
7
332
3418
40
208
303
3214
127
1071
207
2284
174
1593
122
1425
Audiology
64 [38004489]
8.2e-01
4.5e-01
—
—
2.8e+00
1.6e+00
5.5e-01
cases:4.66%
controls:2.10%
cases:1.46%
controls:0.93%
—
—
—
—
cases:2.33%
controls:0.15%
cases:4.49%
controls:0.92%
cases:5.07%
controls:2.98%
16
72
327
3353
5
32
338
3393
—
—
8
5
335
3417
15
31
319
3324
15
90
281
2928
Flexible laryngoscopy
UDQ12 [2001301827]
—
—
—
1.0e+50
—
2.0e+00
2.4e+00
—
—
—
—
—
—
cases:4.66%
controls:0.00%
—
—
cases:1.80%
controls:0.24%
cases:3.72%
controls:0.36%
—
—
—
16
0
327
3425
—
6
8
328
3347
11
11
285
3007
Sleep apnoea
G47.3 [45562094]
7.3e-01
1.1e+00
1.6e+00
—
1.0e+00
1.5e+00
9.1e-01
cases:8.16%
controls:4.12%
cases:7.29%
controls:2.48%
cases:1.46%
controls:0.29%
—
—
cases:1.46%
controls:0.53%
cases:9.88%
controls:2.50%
cases:13.51%
controls:5.93%
28
141
315
3284
25
85
318
3340
5
10
338
3415
—
5
18
338
3404
33
84
301
3271
40
179
256
2839
Dentistry
C5 [903277]
-1.7e-01
—
—
—
2.2e+00
2.0e+00
7.4e-01
cases:1.75%
controls:2.07%
—
—
—
—
—
—
cases:1.75%
controls:0.20%
cases:5.09%
controls:0.69%
cases:4.39%
controls:2.15%
6
71
337
3354
—
—
—
6
7
337
3415
17
23
317
3332
13
65
283
2953
Dysphagia
R13 [45573013]
—
—
—
—
—
2.0e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:1.80%
controls:0.24%
cases:4.39%
controls:0.60%
—
—
—
—
—
6
8
328
3347
13
18
283
3000
Medical Oncology
90 [38004507]
-2.2e-01
2.0e-01
—
—
1.6e+00
1.7e+00
7.9e-01
cases:2.92%
controls:3.62%
cases:3.50%
controls:2.89%
—
—
—
—
cases:4.37%
controls:0.94%
cases:12.28%
controls:2.50%
cases:8.45%
controls:4.01%
10
124
333
3301
12
99
331
3326
—
—
15
32
328
3390
41
84
293
3271
25
121
271
2897
dexamethasone and antiinfectives
S02CA06 [21605178]
4.8e-01
1.7e+00
—
—
—
2.5e+00
1.6e+00
cases:1.46%
controls:0.91%
cases:1.46%
controls:0.26%
—
—
—
—
—
—
cases:2.10%
controls:0.18%
cases:3.72%
controls:0.80%
5
31
338
3394
5
9
338
3416
—
—
—
7
6
327
3349
11
24
285
2994
Pharmacy visit
OMOP4822462 [581458]
5.8e-02
7.8e-01
5.2e-01
1.2e+00
6.3e-01
8.2e-01
5.7e-01
cases:92.42%
controls:92.00%
cases:90.67%
controls:81.61%
cases:55.98%
controls:43.15%
cases:6.41%
controls:1.96%
cases:59.18%
controls:43.54%
cases:91.32%
controls:82.27%
cases:96.96%
controls:94.73%
317
3151
26
274
311
2795
32
630
192
1478
151
1947
22
67
321
3358
203
1490
140
1932
305
2760
29
595
287
2859
9
159
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.2e-01
3.0e-01
9.9e-01
2.2e+00
8.0e-01
2.8e-01
1.3e-01
cases:27.41%
controls:25.11%
cases:24.78%
controls:19.65%
cases:9.04%
controls:3.56%
cases:1.75%
controls:0.20%
cases:8.45%
controls:3.97%
cases:27.25%
controls:22.09%
cases:42.57%
controls:39.36%
94
860
249
2565
85
673
258
2752
31
122
312
3303
6
7
337
3418
29
136
314
3286
91
741
243
2614
126
1188
170
1830
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
9.2e-02
3.2e-01
1.0e+00
2.8e+00
7.2e-01
4.1e-01
3.5e-01
cases:22.74%
controls:21.17%
cases:22.45%
controls:17.43%
cases:9.33%
controls:3.59%
cases:2.33%
controls:0.15%
cases:7.29%
controls:3.68%
cases:26.05%
controls:18.96%
cases:43.24%
controls:35.02%
78
725
265
2700
77
597
266
2828
32
123
311
3302
8
5
335
3420
25
126
318
3296
87
636
247
2719
128
1057
168
1961
Inpatient Hospital
21 [8717]
1.4e-01
4.1e-01
1.2e+00
1.0e+50
1.8e+00
6.8e-01
3.4e-01
cases:34.40%
controls:31.33%
cases:14.58%
controls:10.19%
cases:3.50%
controls:1.05%
cases:7.87%
controls:0.00%
cases:7.29%
controls:1.23%
cases:17.37%
controls:9.66%
cases:28.38%
controls:21.97%
118
1073
225
2352
50
349
293
3076
12
36
331
3389
27
0
316
3425
25
42
318
3380
58
324
276
3031
84
663
212
2355
nystatin; oral
A07AA02 [21600604]
6.4e-01
—
—
—
—
2.2e+00
1.5e+00
cases:1.75%
controls:0.93%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.30%
cases:3.38%
controls:0.76%
6
32
337
3393
—
—
—
—
9
10
325
3345
10
23
286
2995
Outpatient Hospital
22 [8756]
2.0e-01
3.4e-01
1.1e+00
1.0e+50
2.1e+00
1.1e+00
5.1e-01
cases:27.99%
controls:24.12%
cases:9.33%
controls:6.80%
cases:2.04%
controls:0.70%
cases:7.87%
controls:0.00%
cases:7.29%
controls:0.99%
cases:15.87%
controls:6.08%
cases:22.30%
controls:14.74%
96
826
247
2599
32
233
311
3192
7
24
336
3401
27
0
316
3425
25
34
318
3388
53
204
281
3151
66
445
230
2573
Inpatient Visit
IP [9201]
9.1e-02
4.6e-01
—
—
2.5e+00
1.1e+00
5.4e-01
cases:5.54%
controls:5.08%
cases:4.08%
controls:2.63%
—
—
—
—
cases:2.04%
controls:0.18%
cases:6.59%
controls:2.35%
cases:13.51%
controls:8.32%
19
174
324
3251
14
90
329
3335
—
—
7
6
336
3416
22
79
312
3276
40
251
256
2767
Pulmonary Disease
29 [38004472]
6.9e-01
8.2e-01
1.1e+00
—
1.2e+00
1.1e+00
8.4e-01
cases:14.58%
controls:7.91%
cases:10.50%
controls:4.93%
cases:2.62%
controls:0.91%
—
—
cases:3.21%
controls:0.96%
cases:12.57%
controls:4.41%
cases:19.26%
controls:9.38%
50
271
293
3154
36
169
307
3256
9
31
334
3394
—
11
33
332
3389
42
148
292
3207
57
283
239
2735
Asthma, unspecified
J45.9 [45562456]
1.0e+00
1.3e+00
—
—
—
1.1e+00
5.6e-01
cases:6.71%
controls:2.54%
cases:3.79%
controls:1.05%
—
—
—
—
—
—
cases:4.19%
controls:1.43%
cases:6.42%
controls:3.78%
23
87
320
3338
13
36
330
3389
—
—
—
14
48
320
3307
19
114
277
2904
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
3.6e-01
1.9e-01
1.4e+00
—
1.2e+00
2.5e-01
6.4e-01
cases:21.28%
controls:15.85%
cases:10.79%
controls:9.05%
cases:3.79%
controls:0.99%
—
—
cases:3.50%
controls:1.05%
cases:11.68%
controls:9.36%
cases:36.15%
controls:23.06%
73
543
270
2882
37
310
306
3115
13
34
330
3391
—
12
36
331
3386
39
314
295
3041
107
696
189
2322
Differential panel, method unspecified - Blood
69738-3 [42870588]
5.1e-01
4.3e-01
1.5e+00
—
5.4e-01
7.8e-01
7.1e-01
cases:9.04%
controls:5.61%
cases:6.12%
controls:4.06%
cases:3.21%
controls:0.73%
—
—
cases:1.75%
controls:1.02%
cases:8.38%
controls:4.02%
cases:16.55%
controls:8.88%
31
192
312
3233
21
139
322
3286
11
25
332
3400
—
6
35
337
3387
28
135
306
3220
49
268
247
2750
cefalexin; oral
J01DB01 [21602870]
3.6e-01
8.0e-01
1.5e+00
—
1.0e+00
6.0e-01
4.2e-01
cases:36.15%
controls:28.35%
cases:16.62%
controls:8.20%
cases:5.25%
controls:1.17%
—
—
cases:2.92%
controls:1.05%
cases:15.27%
controls:8.97%
cases:34.80%
controls:26.01%
124
971
219
2454
57
281
286
3144
18
40
325
3385
—
10
36
333
3386
51
301
283
3054
103
785
193
2233
Radiotherapy with large shaped fields - isocentric therapy
ZX012 [2001311468]
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.15%
—
—
—
—
—
—
—
9
5
325
3350
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
5.1e-01
5.4e-01
—
—
2.9e+00
5.7e-01
2.8e-01
cases:6.41%
controls:3.94%
cases:2.04%
controls:1.20%
—
—
—
—
cases:2.62%
controls:0.15%
cases:2.40%
controls:1.37%
cases:5.07%
controls:3.88%
22
135
321
3290
7
41
336
3384
—
—
9
5
334
3417
8
46
326
3309
15
117
281
2901
dexamethasone and antiinfectives
S03CA01 [21605206]
4.9e-01
1.4e+00
—
—
—
1.8e+00
1.1e+00
cases:2.92%
controls:1.81%
cases:2.33%
controls:0.58%
—
—
—
—
—
—
cases:2.40%
controls:0.39%
cases:6.76%
controls:2.45%
10
62
333
3363
8
20
335
3405
—
—
—
8
13
326
3342
20
74
276
2944
Malignant tumour
130 [2001600128]
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.99%
controls:0.18%
—
—
—
—
—
—
—
10
6
324
3349
—
Rhinopharyngoscopy
UDH02 [2001301680]
1.0e+00
—
—
1.0e+50
—
—
2.8e+00
cases:2.33%
controls:0.85%
—
—
—
—
cases:2.62%
controls:0.00%
—
—
—
—
cases:4.05%
controls:0.27%
8
29
335
3396
—
—
9
0
334
3425
—
—
12
8
284
3010
Oncology Clinic/Center
261QX0200X [38004268]
3.7e-01
1.3e-01
—
1.0e+50
—
1.9e+00
8.3e-01
cases:7.00%
controls:4.96%
cases:1.46%
controls:1.28%
—
—
cases:1.46%
controls:0.00%
—
—
cases:5.99%
controls:0.92%
cases:9.12%
controls:4.17%
24
170
319
3255
5
44
338
3381
—
5
0
338
3425
—
20
31
314
3324
27
126
269
2892
General anaesthesia
WX402 [2001310806]
2.3e-01
5.2e-01
—
—
—
1.7e+00
9.3e-01
cases:1.75%
controls:1.40%
cases:1.46%
controls:0.88%
—
—
—
—
—
—
cases:4.19%
controls:0.77%
cases:7.77%
controls:3.21%
6
48
337
3377
5
30
338
3395
—
—
—
14
26
320
3329
23
97
273
2921
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
6.5e-01
6.8e-01
9.7e-01
—
9.2e-01
1.1e+00
8.9e-01
cases:11.37%
controls:6.28%
cases:4.96%
controls:2.57%
cases:1.46%
controls:0.55%
—
—
cases:1.46%
controls:0.58%
cases:6.59%
controls:2.32%
cases:14.53%
controls:6.49%
39
215
304
3210
17
88
326
3337
5
19
338
3406
—
5
20
338
3402
22
78
312
3277
43
196
253
2822
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.3e-01
3.6e-01
1.2e+00
—
7.5e-01
7.0e-01
6.7e-01
cases:11.37%
controls:8.41%
cases:7.87%
controls:5.61%
cases:3.50%
controls:1.05%
—
—
cases:2.62%
controls:1.26%
cases:10.78%
controls:5.63%
cases:22.30%
controls:12.79%
39
288
304
3137
27
192
316
3233
12
36
331
3389
—
9
43
334
3379
36
189
298
3166
66
386
230
2632
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.4e-01
5.0e-01
7.0e-01
—
9.3e-01
5.3e-01
6.4e-01
cases:38.48%
controls:30.77%
cases:24.49%
controls:16.44%
cases:5.83%
controls:2.98%
—
—
cases:6.71%
controls:2.75%
cases:23.65%
controls:15.47%
cases:53.38%
controls:37.74%
132
1054
211
2371
84
563
259
2862
20
102
323
3323
—
23
94
320
3328
79
519
255
2836
158
1139
138
1879
Nonallergic asthma
J45.1 [45557625]
1.1e+00
—
—
—
—
2.6e+00
1.4e+00
cases:2.04%
controls:0.70%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.21%
cases:2.70%
controls:0.70%
7
24
336
3401
—
—
—
—
9
7
325
3348
8
21
288
2997
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.1e-01
3.6e-01
1.2e+00
—
7.5e-01
7.0e-01
6.5e-01
cases:11.08%
controls:8.41%
cases:7.87%
controls:5.64%
cases:3.50%
controls:1.05%
—
—
cases:2.62%
controls:1.26%
cases:10.78%
controls:5.66%
cases:21.96%
controls:12.79%
38
288
305
3137
27
193
316
3232
12
36
331
3389
—
9
43
334
3379
36
190
298
3165
65
386
231
2632
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.4e-01
3.6e-01
1.2e+00
—
7.5e-01
6.7e-01
6.7e-01
cases:11.37%
controls:8.35%
cases:7.87%
controls:5.61%
cases:3.50%
controls:1.05%
—
—
cases:2.62%
controls:1.26%
cases:10.48%
controls:5.63%
cases:22.30%
controls:12.82%
39
286
304
3139
27
192
316
3233
12
36
331
3389
—
9
43
334
3379
35
189
299
3166
66
387
230
2631
Infiltration anesthesia
WX110 [2001310767]
2.1e-01
2.9e-01
3.9e-01
—
1.3e+00
7.2e-01
4.9e-01
cases:23.62%
controls:20.00%
cases:9.04%
controls:6.89%
cases:1.46%
controls:0.99%
—
—
cases:4.08%
controls:1.11%
cases:14.37%
controls:7.54%
cases:30.41%
controls:21.11%
81
685
262
2740
31
236
312
3189
5
34
338
3391
—
14
38
329
3384
48
253
286
3102
90
637
206
2381
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
2.8e-01
3.3e-01
1.2e+00
—
7.3e-01
6.7e-01
6.3e-01
cases:11.08%
controls:8.58%
cases:7.87%
controls:5.81%
cases:3.50%
controls:1.05%
—
—
cases:2.62%
controls:1.29%
cases:10.78%
controls:5.84%
cases:22.97%
controls:13.65%
38
294
305
3131
27
199
316
3226
12
36
331
3389
—
9
44
334
3378
36
196
298
3159
68
412
228
2606
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
—
-1.0e+50
—
—
—
2.5e+00
1.2e+00
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
cases:1.80%
controls:0.15%
cases:2.03%
controls:0.63%
—
0
6
343
3419
—
—
—
6
5
328
3350
6
19
290
2999
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
-3.0e-01
9.6e-01
—
—
—
1.5e+00
9.8e-01
cases:1.75%
controls:2.34%
cases:2.33%
controls:0.91%
—
—
—
—
—
—
cases:3.29%
controls:0.75%
cases:6.42%
controls:2.52%
6
80
337
3345
8
31
335
3394
—
—
—
11
25
323
3330
19
76
277
2942
General Practice Dentistry
1223G0001X [38003675]
1.5e+00
—
—
—
—
2.5e+00
1.5e+00
cases:1.75%
controls:0.41%
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.21%
cases:2.36%
controls:0.56%
6
14
337
3411
—
—
—
—
8
7
326
3348
7
17
289
3001
Physiotherapist
Z3226 [2001311560]
4.6e-01
—
—
—
—
2.3e+00
1.2e+00
cases:3.79%
controls:2.42%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.27%
cases:3.04%
controls:0.93%
13
83
330
3342
—
—
—
—
9
9
325
3346
9
28
287
2990
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.80%
controls:0.18%
—
—
—
—
—
—
—
6
6
328
3349
—
Counselling and guidance which enhance independent living
R2130 [2001310196]
5.8e-01
—
—
—
1.0e+50
2.2e+00
1.2e+00
cases:1.46%
controls:0.82%
—
—
—
—
—
—
cases:2.04%
controls:0.00%
cases:2.99%
controls:0.33%
cases:3.38%
controls:0.99%
5
28
338
3397
—
—
—
7
0
336
3422
10
11
324
3344
10
30
286
2988
Office Visit
OMOP4822458 [581477]
1.7e-01
6.2e-02
1.0e+00
—
2.2e+00
5.9e-01
-3.1e-02
cases:9.91%
controls:8.50%
cases:2.92%
controls:2.74%
cases:1.46%
controls:0.53%
—
—
cases:2.62%
controls:0.29%
cases:4.49%
controls:2.53%
cases:6.08%
controls:6.26%
34
291
309
3134
10
94
333
3331
5
18
338
3407
—
9
10
334
3412
15
85
319
3270
18
189
278
2829
oxycodone; oral, parenteral
N02AA05 [21604260]
—
—
—
—
—
2.2e+00
4.3e-01
—
—
—
—
—
—
—
—
—
—
cases:5.69%
controls:0.66%
cases:3.38%
controls:2.22%
—
—
—
—
—
19
22
315
3333
10
67
286
2951
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.27%
—
—
—
—
—
—
—
8
9
326
3346
—
Neck ultrasound examination
EP1AE [2001302284]
1.3e+00
—
—
—
—
—
2.1e+00
cases:1.75%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:0.56%
6
17
337
3408
—
—
—
—
—
13
17
283
3001
fluticasone furoate; nasal
R01AD12 [21605053]
3.9e-01
3.0e-01
2.1e+00
—
—
5.9e-01
3.0e-01
cases:12.24%
controls:8.61%
cases:4.66%
controls:3.50%
cases:2.92%
controls:0.38%
—
—
—
—
cases:6.59%
controls:3.76%
cases:10.81%
controls:8.25%
42
295
301
3130
16
120
327
3305
10
13
333
3412
—
—
22
126
312
3229
32
249
264
2769
fluticasone; nasal
R01AD08 [21605050]
3.9e-01
3.0e-01
2.1e+00
—
—
5.9e-01
3.0e-01
cases:12.24%
controls:8.61%
cases:4.66%
controls:3.50%
cases:2.92%
controls:0.38%
—
—
—
—
cases:6.59%
controls:3.76%
cases:10.81%
controls:8.25%
42
295
301
3130
16
120
327
3305
10
13
333
3412
—
—
22
126
312
3229
32
249
264
2769
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.27%
—
—
—
—
—
—
6
8
290
3010
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
9.7e-01
—
—
—
—
2.0e+00
6.6e-01
cases:1.75%
controls:0.67%
—
—
—
—
—
—
—
—
cases:1.80%
controls:0.24%
cases:2.03%
controls:1.06%
6
23
337
3402
—
—
—
—
6
8
328
3347
6
32
290
2986
Bacterial infection, unspecified
A49.9 [45590816]
—
—
—
—
—
2.0e+00
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:1.80%
controls:0.24%
cases:2.36%
controls:0.86%
—
—
—
—
—
6
8
328
3347
7
26
289
2992
dutasteride; oral
G04CB02 [21602676]
—
2.0e+00
—
—
—
—
—
—
—
cases:1.75%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
6
8
337
3417
—
—
—
—
—
codeine and paracetamol
N02AJ06 [1123647]
3.9e-01
4.2e-01
1.2e+00
—
1.3e+00
7.0e-01
5.0e-01
cases:17.49%
controls:12.58%
cases:7.00%
controls:4.70%
cases:2.33%
controls:0.70%
—
—
cases:3.21%
controls:0.88%
cases:9.88%
controls:5.16%
cases:20.27%
controls:13.32%
60
431
283
2994
24
161
319
3264
8
24
335
3401
—
11
30
332
3392
33
173
301
3182
60
402
236
2616
Osmolality of Urine
2695-5 [3026782]
3.6e-01
7.9e-01
—
—
—
1.1e+00
9.0e-01
cases:5.25%
controls:3.71%
cases:2.92%
controls:1.34%
—
—
—
—
—
—
cases:4.19%
controls:1.43%
cases:7.43%
controls:3.15%
18
127
325
3298
10
46
333
3379
—
—
—
14
48
320
3307
22
95
274
2923
metronidazole and furazolidone
P01AB51 [45893518]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.33%
—
—
—
—
—
—
7
10
289
3008
nystatin
D01AA01 [21601911]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.33%
—
—
—
—
—
—
7
10
289
3008
nystatin; vaginal
G01AA01 [21602363]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.33%
—
—
—
—
—
—
7
10
289
3008
triamcinolone and antiinfectives
S02CA04 [21605176]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.33%
—
—
—
—
—
—
7
10
289
3008
Thorax X-ray examination
GD1AA [2001303617]
2.8e-01
5.4e-01
1.7e+00
—
1.7e+00
1.2e+00
8.2e-01
cases:10.50%
controls:8.12%
cases:5.25%
controls:3.12%
cases:1.46%
controls:0.26%
—
—
cases:1.75%
controls:0.32%
cases:7.49%
controls:2.47%
cases:16.22%
controls:7.85%
36
278
307
3147
18
107
325
3318
5
9
338
3416
—
6
11
337
3411
25
83
309
3272
48
237
248
2781
antibiotics in combination with corticosteroids
D01AA20 [21601918]
2.0e-01
—
—
—
—
2.0e+00
8.6e-01
cases:1.46%
controls:1.20%
—
—
—
—
—
—
—
—
cases:2.10%
controls:0.30%
cases:2.70%
controls:1.16%
5
41
338
3384
—
—
—
—
7
10
327
3345
8
35
288
2983
Impacted cerumen
H61.2 [45562307]
2.0e+00
—
—
—
—
-1.0e+50
9.9e-01
cases:2.04%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:2.36%
controls:0.89%
7
10
336
3415
—
—
—
—
0
11
334
3344
7
27
289
2991
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
—
—
—
—
1.9e+00
7.9e-01
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.36%
cases:3.38%
controls:1.56%
—
—
—
—
—
8
12
326
3343
10
47
286
2971
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.1e+00
—
—
—
—
1.9e+00
9.6e-01
cases:2.92%
controls:1.02%
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.36%
cases:4.39%
controls:1.72%
10
35
333
3390
—
—
—
—
8
12
326
3343
13
52
283
2966
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
-1.0e+50
—
—
—
—
1.9e+00
1.0e+00
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.36%
cases:2.03%
controls:0.73%
0
29
343
3396
—
—
—
—
8
12
326
3343
6
22
290
2996
INR in Blood by Coagulation assay
34714-6 [3032080]
6.0e-01
5.7e-01
5.2e-01
—
5.7e-01
7.6e-01
5.5e-01
cases:13.12%
controls:7.68%
cases:7.87%
controls:4.61%
cases:2.92%
controls:1.75%
—
—
cases:2.92%
controls:1.67%
cases:10.48%
controls:5.19%
cases:18.92%
controls:11.90%
45
263
298
3162
27
158
316
3267
10
60
333
3365
—
10
57
333
3365
35
174
299
3181
56
359
240
2659
Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence
14277-8 [3004383]
-1.0e+50
—
—
—
—
—
1.9e+00
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.36%
0
13
343
3412
—
—
—
—
—
7
11
289
3007
Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence
14278-6 [3003284]
-1.0e+50
—
—
—
—
—
1.9e+00
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.36%
0
13
343
3412
—
—
—
—
—
7
11
289
3007
X-ray mammography
HA1AA [2001303884]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.36%
—
—
—
—
—
—
7
11
289
3007
esomeprazole; oral, parenteral
A02BC05 [21600100]
4.7e-01
7.6e-01
4.5e-01
—
1.1e+00
1.2e+00
6.8e-01
cases:11.66%
controls:7.65%
cases:7.29%
controls:3.56%
cases:1.46%
controls:0.93%
—
—
cases:2.62%
controls:0.85%
cases:11.68%
controls:3.96%
cases:14.86%
controls:8.12%
40
262
303
3163
25
122
318
3303
5
32
338
3393
—
9
29
334
3393
39
133
295
3222
44
245
252
2773
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
-3.2e-01
7.9e-01
-1.0e+50
—
—
1.8e+00
2.6e-01
cases:2.62%
controls:3.56%
cases:2.92%
controls:1.34%
cases:0.00%
controls:0.20%
—
—
—
—
cases:6.89%
controls:1.16%
cases:4.73%
controls:3.68%
9
122
334
3303
10
46
333
3379
0
7
343
3418
—
—
23
39
311
3316
14
111
282
2907
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
1.9e-01
—
—
—
—
1.8e+00
6.2e-01
cases:2.33%
controls:1.93%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.45%
cases:5.41%
controls:2.98%
8
66
335
3359
—
—
—
—
9
15
325
3340
16
90
280
2928
Simple examination of mouth
SAA01 [2001310274]
2.1e-01
6.6e-01
—
—
1.1e+00
2.9e-01
2.4e-01
cases:25.66%
controls:21.90%
cases:17.49%
controls:9.87%
—
—
—
—
cases:3.79%
controls:1.26%
cases:13.47%
controls:10.46%
cases:31.76%
controls:26.77%
88
750
255
2675
60
338
283
3087
—
—
13
43
330
3379
45
351
289
3004
94
808
202
2210
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
3.1e-01
3.9e-01
1.2e+00
—
7.5e-01
6.1e-01
5.6e-01
cases:11.08%
controls:8.35%
cases:8.16%
controls:5.69%
cases:3.50%
controls:1.05%
—
—
cases:2.62%
controls:1.26%
cases:9.88%
controls:5.60%
cases:21.62%
controls:13.59%
38
286
305
3139
28
195
315
3230
12
36
331
3389
—
9
43
334
3379
33
188
301
3167
64
410
232
2608
Pathology report gross observation
24419-4 [3002256]
-2.6e-01
9.3e-01
—
—
—
1.8e+00
4.9e-01
cases:2.04%
controls:2.63%
cases:1.75%
controls:0.70%
—
—
—
—
—
—
cases:3.89%
controls:0.69%
cases:4.05%
controls:2.52%
7
90
336
3335
6
24
337
3401
—
—
—
13
23
321
3332
12
76
284
2942
Basophils [#/volume] in Blood
26444-0 [3006315]
3.0e-01
4.6e-01
1.1e+00
—
7.3e-01
6.0e-01
6.5e-01
cases:11.66%
controls:8.88%
cases:9.33%
controls:6.07%
cases:3.79%
controls:1.28%
—
—
cases:2.92%
controls:1.43%
cases:10.78%
controls:6.20%
cases:23.99%
controls:14.12%
40
304
303
3121
32
208
311
3217
13
44
330
3381
—
10
49
333
3373
36
208
298
3147
71
426
225
2592
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
6.6e-01
—
—
—
—
1.8e+00
2.9e-01
cases:3.50%
controls:1.84%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.48%
cases:3.04%
controls:2.29%
12
63
331
3362
—
—
—
—
9
16
325
3339
9
69
287
2949
Monocytes [#/volume] in Blood
26484-6 [3001604]
2.7e-01
4.6e-01
1.1e+00
—
7.1e-01
6.1e-01
6.4e-01
cases:11.37%
controls:8.91%
cases:9.33%
controls:6.07%
cases:3.79%
controls:1.28%
—
—
cases:2.92%
controls:1.46%
cases:10.78%
controls:6.17%
cases:23.65%
controls:14.05%
39
305
304
3120
32
208
311
3217
13
44
330
3381
—
10
50
333
3372
36
207
298
3148
70
424
226
2594
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
3.2e-01
8.4e-01
—
—
—
1.1e+00
6.4e-01
cases:10.20%
controls:7.59%
cases:4.66%
controls:2.07%
—
—
—
—
—
—
cases:5.69%
controls:1.97%
cases:13.51%
controls:7.59%
35
260
308
3165
16
71
327
3354
—
—
—
19
66
315
3289
40
229
256
2789
Immunohistochemistry procedure
117617002 [4035726]
2.3e-01
—
—
1.0e+50
—
1.7e+00
3.5e-01
cases:1.75%
controls:1.40%
—
—
—
—
cases:2.62%
controls:0.00%
—
—
cases:2.99%
controls:0.54%
cases:1.69%
controls:1.19%
6
48
337
3377
—
—
9
0
334
3425
—
10
18
324
3337
5
36
291
2982
FEV1/FVC --post bronchodilation
69970-2 [42868459]
7.3e-01
—
—
—
—
—
1.7e+00
cases:2.92%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:5.41%
controls:0.99%
10
49
333
3376
—
—
—
—
—
16
30
280
2988
FEV1 --post bronchodilation
20155-8 [3023550]
7.3e-01
—
—
—
—
—
1.7e+00
cases:2.92%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:5.41%
controls:0.99%
10
49
333
3376
—
—
—
—
—
16
30
280
2988
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
7.3e-01
—
—
—
—
—
1.7e+00
cases:2.92%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:5.41%
controls:0.99%
10
49
333
3376
—
—
—
—
—
16
30
280
2988
FVC percent change Respiratory system
69982-7 [42868471]
7.3e-01
—
—
—
—
—
1.7e+00
cases:2.92%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:5.41%
controls:0.99%
10
49
333
3376
—
—
—
—
—
16
30
280
2988
FEV1 percent change
69983-5 [42868472]
7.3e-01
—
—
—
—
—
1.7e+00
cases:2.92%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:5.41%
controls:0.99%
10
49
333
3376
—
—
—
—
—
16
30
280
2988
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
-1.7e-01
1.7e-01
—
—
—
9.4e-01
7.8e-01
cases:3.21%
controls:3.77%
cases:2.62%
controls:2.22%
—
—
—
—
—
—
cases:5.39%
controls:2.18%
cases:11.49%
controls:5.60%
11
129
332
3296
9
76
334
3349
—
—
—
18
73
316
3282
34
169
262
2849
FEV1/FVC
19926-5 [3011505]
7.6e-01
—
—
—
—
1.2e+00
1.7e+00
cases:3.50%
controls:1.66%
—
—
—
—
—
—
—
—
cases:1.50%
controls:0.48%
cases:5.41%
controls:1.03%
12
57
331
3368
—
—
—
—
5
16
329
3339
16
31
280
2987
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
7.6e-01
—
—
—
—
1.2e+00
1.7e+00
cases:3.50%
controls:1.66%
—
—
—
—
—
—
—
—
cases:1.50%
controls:0.48%
cases:5.41%
controls:1.03%
12
57
331
3368
—
—
—
—
5
16
329
3339
16
31
280
2987
FEV1
20150-9 [3024653]
7.6e-01
—
—
—
—
1.2e+00
1.7e+00
cases:3.50%
controls:1.66%
—
—
—
—
—
—
—
—
cases:1.50%
controls:0.48%
cases:5.41%
controls:1.03%
12
57
331
3368
—
—
—
—
5
16
329
3339
16
31
280
2987
ibuprofen
R02AX02 [1588667]
2.5e-01
4.2e-01
6.4e-01
—
1.2e+00
4.2e-01
4.4e-01
cases:39.65%
controls:33.96%
cases:20.99%
controls:14.83%
cases:4.37%
controls:2.36%
—
—
cases:5.83%
controls:1.78%
cases:20.96%
controls:14.78%
cases:45.27%
controls:34.69%
136
1163
207
2262
72
508
271
2917
15
81
328
3344
—
20
61
323
3361
70
496
264
2859
134
1047
162
1971
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
2.5e-01
4.2e-01
6.4e-01
—
1.2e+00
4.2e-01
4.4e-01
cases:39.65%
controls:33.96%
cases:20.99%
controls:14.83%
cases:4.37%
controls:2.36%
—
—
cases:5.83%
controls:1.78%
cases:20.96%
controls:14.78%
cases:45.27%
controls:34.69%
136
1163
207
2262
72
508
271
2917
15
81
328
3344
—
20
61
323
3361
70
496
264
2859
134
1047
162
1971
Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.04%
controls:0.60%
—
—
—
—
—
—
9
18
287
3000
Left side
ZXA05 [2001311347]
2.7e-01
—
—
—
—
1.6e+00
8.9e-01
cases:4.37%
controls:3.39%
—
—
—
—
—
—
—
—
cases:2.99%
controls:0.60%
cases:5.41%
controls:2.29%
15
116
328
3309
—
—
—
—
10
20
324
3335
16
69
280
2949
zopiclone; oral
N05CF01 [21604654]
5.6e-01
7.6e-01
5.4e-01
—
6.7e-01
8.3e-01
6.3e-01
cases:11.37%
controls:6.80%
cases:7.87%
controls:3.82%
cases:1.75%
controls:1.02%
—
—
cases:1.75%
controls:0.91%
cases:8.38%
controls:3.85%
cases:12.50%
controls:7.09%
39
233
304
3192
27
131
316
3294
6
35
337
3390
—
6
31
337
3391
28
129
306
3226
37
214
259
2804
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
7.6e-01
-1.0e+50
—
—
—
1.6e+00
9.1e-01
cases:2.33%
controls:1.11%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:3.89%
controls:0.83%
cases:4.39%
controls:1.82%
8
38
335
3387
0
18
343
3407
—
—
—
13
28
321
3327
13
55
283
2963
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
3.9e-01
1.9e-01
—
—
1.2e+00
9.0e-01
6.5e-01
cases:9.62%
controls:6.72%
cases:4.96%
controls:4.12%
—
—
—
—
cases:2.92%
controls:0.88%
cases:10.18%
controls:4.41%
cases:19.59%
controls:11.30%
33
230
310
3195
17
141
326
3284
—
—
10
30
333
3392
34
148
300
3207
58
341
238
2677
Tooth X-ray additional picture
EB1CA [2001301909]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.72%
controls:0.83%
—
—
—
—
—
—
11
25
285
2993
Respiratory and circulatory monitoring
WX700 [2001310817]
-1.8e-02
—
—
—
-1.0e+50
1.3e+00
1.5e+00
cases:1.75%
controls:1.78%
—
—
—
—
—
—
cases:0.00%
controls:0.18%
cases:1.50%
controls:0.42%
cases:5.41%
controls:1.23%
6
61
337
3364
—
—
—
0
6
343
3416
5
14
329
3341
16
37
280
2981
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
9.2e-02
1.5e+00
—
—
—
—
2.1e-01
cases:2.33%
controls:2.13%
cases:2.62%
controls:0.58%
—
—
—
—
—
—
—
—
cases:3.04%
controls:2.49%
8
73
335
3352
9
20
334
3405
—
—
—
—
9
75
287
2943
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
6.4e-01
—
—
—
—
1.2e+00
1.5e+00
cases:2.62%
controls:1.40%
—
—
—
—
—
—
—
—
cases:1.50%
controls:0.48%
cases:7.09%
controls:1.66%
9
48
334
3377
—
—
—
—
5
16
329
3339
21
50
275
2968
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
7.6e-01
—
—
—
—
1.6e+00
1.5e+00
cases:2.04%
controls:0.96%
—
—
—
—
—
—
—
—
cases:1.50%
controls:0.30%
cases:5.41%
controls:1.26%
7
33
336
3392
—
—
—
—
5
10
329
3345
16
38
280
2980
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2.8e-01
—
-1.0e+50
—
—
1.5e+00
4.5e-01
cases:2.33%
controls:1.78%
—
—
cases:0.00%
controls:0.15%
—
—
—
—
cases:5.69%
controls:1.34%
cases:5.41%
controls:3.51%
8
61
335
3364
—
0
5
343
3420
—
—
19
45
315
3310
16
106
280
2912
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
5.4e-01
1.5e+00
—
—
—
8.1e-01
5.1e-01
cases:6.12%
controls:3.68%
cases:4.96%
controls:1.17%
—
—
—
—
—
—
cases:2.69%
controls:1.22%
cases:7.77%
controls:4.80%
21
126
322
3299
17
40
326
3385
—
—
—
9
41
325
3314
23
145
273
2873
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.38%
controls:0.80%
—
—
—
—
—
—
10
24
286
2994
Treatment plan or consultation
WZC00 [2001310885]
5.2e-01
5.4e-01
1.9e+00
—
1.6e+00
1.4e+00
6.6e-01
cases:7.87%
controls:4.85%
cases:3.50%
controls:2.07%
cases:1.75%
controls:0.26%
—
—
cases:1.75%
controls:0.35%
cases:6.89%
controls:1.76%
cases:11.15%
controls:6.06%
27
166
316
3259
12
71
331
3354
6
9
337
3416
—
6
12
337
3410
23
59
311
3296
33
183
263
2835
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.72%
controls:0.96%
—
—
—
—
—
—
11
29
285
2989
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
8.7e-01
—
—
—
—
-1.0e+50
1.4e+00
cases:1.46%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:4.05%
controls:1.06%
5
21
338
3404
—
—
—
—
0
9
334
3346
12
32
284
2986
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.8e-01
4.4e-01
7.9e-01
—
8.0e-01
8.5e-01
4.9e-01
cases:12.83%
controls:10.95%
cases:11.08%
controls:7.42%
cases:3.79%
controls:1.75%
—
—
cases:4.37%
controls:2.02%
cases:15.57%
controls:7.33%
cases:23.99%
controls:16.14%
44
375
299
3050
38
254
305
3171
13
60
330
3365
—
15
69
328
3353
52
246
282
3109
71
487
225
2531
fluconazole; oral, parenteral
J02AC01 [21603080]
4.3e-01
5.5e-01
—
—
—
1.3e+00
5.1e-01
cases:8.75%
controls:5.87%
cases:3.21%
controls:1.87%
—
—
—
—
—
—
cases:6.59%
controls:1.88%
cases:8.45%
controls:5.27%
30
201
313
3224
11
64
332
3361
—
—
—
22
63
312
3292
25
159
271
2859
orphenadrine, combinations
M03BC51 [21604113]
7.9e-01
1.3e+00
—
—
—
6.7e-01
6.5e-01
cases:5.83%
controls:2.74%
cases:3.21%
controls:0.91%
—
—
—
—
—
—
cases:1.50%
controls:0.77%
cases:4.73%
controls:2.52%
20
94
323
3331
11
31
332
3394
—
—
—
5
26
329
3329
14
76
282
2942
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
1.3e+00
—
—
—
—
—
5.4e-01
cases:3.21%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:1.19%
11
31
332
3394
—
—
—
—
—
6
36
290
2982
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
-1.6e-02
1.0e+00
—
—
—
—
1.3e+00
cases:2.04%
controls:2.07%
cases:1.46%
controls:0.53%
—
—
—
—
—
—
—
—
cases:4.05%
controls:1.19%
7
71
336
3354
5
18
338
3407
—
—
—
—
12
36
284
2982
amoxicillin; oral, parenteral
J01CA04 [21602823]
4.6e-01
7.8e-01
—
—
—
3.2e-01
3.0e-01
cases:29.74%
controls:21.08%
cases:11.66%
controls:5.72%
—
—
—
—
—
—
cases:8.98%
controls:6.68%
cases:26.01%
controls:20.64%
102
722
241
2703
40
196
303
3229
—
—
—
30
224
304
3131
77
623
219
2395
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
1.0e-01
4.8e-01
—
—
1.4e+00
1.2e+00
3.0e-01
cases:4.08%
controls:3.71%
cases:2.62%
controls:1.64%
—
—
—
—
cases:1.46%
controls:0.35%
cases:5.39%
controls:1.70%
cases:7.43%
controls:5.63%
14
127
329
3298
9
56
334
3369
—
—
5
12
338
3410
18
57
316
3298
22
170
274
2848
doxycycline; oral, parenteral
J01AA02 [21602800]
4.6e-01
4.7e-01
9.7e-01
—
—
6.9e-01
7.2e-01
cases:25.36%
controls:17.66%
cases:7.87%
controls:5.05%
cases:1.46%
controls:0.55%
—
—
—
—
cases:8.38%
controls:4.38%
cases:25.34%
controls:14.15%
87
605
256
2820
27
173
316
3252
5
19
338
3406
—
—
28
147
306
3208
75
427
221
2591
More than one and less than three hours
ZXE10 [2001311401]
8.8e-02
6.7e-01
—
—
—
1.2e+00
1.2e+00
cases:6.12%
controls:5.64%
cases:2.92%
controls:1.52%
—
—
—
—
—
—
cases:3.59%
controls:1.10%
cases:8.78%
controls:2.88%
21
193
322
3232
10
52
333
3373
—
—
—
12
37
322
3318
26
87
270
2931
Obesity due to excess calories
E66.01 [2000501501]
3.3e-01
-1.0e+50
—
—
—
-1.0e+50
1.2e+00
cases:1.46%
controls:1.05%
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:4.39%
controls:1.42%
5
36
338
3389
0
13
343
3412
—
—
—
0
16
334
3339
13
43
283
2975
CBC panel - Blood by Automated count
58410-2 [40761511]
1.1e-01
3.3e-01
1.1e+00
—
5.9e-01
2.8e-01
3.1e-01
cases:32.36%
controls:29.99%
cases:26.53%
controls:20.58%
cases:9.62%
controls:3.27%
—
—
cases:6.41%
controls:3.65%
cases:26.95%
controls:21.79%
cases:49.32%
controls:41.55%
111
1027
232
2398
91
705
252
2720
33
112
310
3313
—
22
125
321
3297
90
731
244
2624
146
1254
150
1764
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
3.1e-01
8.8e-01
—
—
1.8e+00
1.1e+00
5.9e-01
cases:4.66%
controls:3.47%
cases:2.92%
controls:1.23%
—
—
—
—
cases:1.46%
controls:0.23%
cases:4.19%
controls:1.37%
cases:7.43%
controls:4.27%
16
119
327
3306
10
42
333
3383
—
—
5
8
338
3414
14
46
320
3309
22
129
274
2889
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.5e-01
3.4e-01
5.4e-01
—
7.4e-01
6.4e-01
4.9e-01
cases:18.66%
controls:16.55%
cases:13.99%
controls:10.39%
cases:3.21%
controls:1.90%
—
—
cases:4.66%
controls:2.28%
cases:19.76%
controls:11.48%
cases:34.80%
controls:24.55%
64
567
279
2858
48
356
295
3069
11
65
332
3360
—
16
78
327
3344
66
385
268
2970
103
741
193
2277
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.3e-02
3.0e-01
1.1e+00
—
6.2e-01
4.0e-01
3.3e-01
cases:21.57%
controls:21.02%
cases:22.45%
controls:17.64%
cases:9.33%
controls:3.24%
—
—
cases:6.12%
controls:3.39%
cases:26.65%
controls:19.58%
cases:43.58%
controls:35.82%
74
720
269
2705
77
604
266
2821
32
111
311
3314
—
21
116
322
3306
89
657
245
2698
129
1081
167
1937
Intravenous general anesthesia
WX404 [2001310807]
3.2e-01
—
—
—
—
1.5e+00
1.1e+00
cases:4.08%
controls:3.01%
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.54%
cases:4.39%
controls:1.49%
14
103
329
3322
—
—
—
—
8
18
326
3337
13
45
283
2973
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
-1.1e-01
4.9e-01
—
—
1.4e+00
1.1e+00
4.6e-01
cases:5.25%
controls:5.81%
cases:3.79%
controls:2.36%
—
—
—
—
cases:1.75%
controls:0.44%
cases:6.89%
controls:2.38%
cases:10.81%
controls:7.12%
18
199
325
3226
13
81
330
3344
—
—
6
15
337
3407
23
80
311
3275
32
215
264
2803
Neurosurgery
14 [38004459]
-4.2e-01
—
—
—
-1.0e+50
6.3e-01
1.1e+00
cases:1.75%
controls:2.63%
—
—
—
—
—
—
cases:0.00%
controls:0.15%
cases:1.50%
controls:0.80%
cases:5.74%
controls:1.99%
6
90
337
3335
—
—
—
0
5
343
3417
5
27
329
3328
17
60
279
2958
finasteride; oral
G04CB01 [21602675]
3.4e-01
7.8e-01
—
—
—
1.0e+00
1.1e+00
cases:2.04%
controls:1.46%
cases:2.33%
controls:1.08%
—
—
—
—
—
—
cases:2.99%
controls:1.07%
cases:4.39%
controls:1.52%
7
50
336
3375
8
37
335
3388
—
—
—
10
36
324
3319
13
46
283
2972
finasteride; oral
D11AX10 [21602350]
3.4e-01
7.8e-01
—
—
—
1.0e+00
1.1e+00
cases:2.04%
controls:1.46%
cases:2.33%
controls:1.08%
—
—
—
—
—
—
cases:2.99%
controls:1.07%
cases:4.39%
controls:1.52%
7
50
336
3375
8
37
335
3388
—
—
—
10
36
324
3319
13
46
283
2972
metronidazole; oral, rectal
P01AB01 [21604857]
4.9e-01
1.0e+00
—
—
—
5.6e-01
3.9e-01
cases:11.37%
controls:7.27%
cases:5.25%
controls:1.93%
—
—
—
—
—
—
cases:2.99%
controls:1.73%
cases:9.12%
controls:6.36%
39
249
304
3176
18
66
325
3359
—
—
—
10
58
324
3297
27
192
269
2826
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
-1.8e-02
7.0e-01
—
—
—
—
1.0e+00
cases:1.75%
controls:1.78%
cases:1.46%
controls:0.73%
—
—
—
—
—
—
—
—
cases:6.42%
controls:2.39%
6
61
337
3364
5
25
338
3400
—
—
—
—
19
72
277
2946
Dental examination
Z01.2 [45581002]
2.5e-01
5.7e-01
—
—
—
1.0e+00
2.4e-01
cases:9.04%
controls:7.18%
cases:4.37%
controls:2.51%
—
—
—
—
—
—
cases:6.89%
controls:2.62%
cases:14.53%
controls:11.83%
31
246
312
3179
15
86
328
3339
—
—
—
23
88
311
3267
43
357
253
2661
lansoprazole; oral
A02BC03 [21600098]
6.9e-01
1.0e+00
—
—
—
9.5e-01
7.4e-01
cases:8.45%
controls:4.44%
cases:4.96%
controls:1.87%
—
—
—
—
—
—
cases:4.79%
controls:1.91%
cases:8.11%
controls:4.04%
29
152
314
3273
17
64
326
3361
—
—
—
16
64
318
3291
24
122
272
2896
temazepam; oral
N05CD07 [21604642]
8.5e-01
1.1e+00
—
—
—
7.7e-01
1.0e+00
cases:5.25%
controls:2.31%
cases:3.21%
controls:1.14%
—
—
—
—
—
—
cases:3.29%
controls:1.55%
cases:6.42%
controls:2.45%
18
79
325
3346
11
39
332
3386
—
—
—
11
52
323
3303
19
74
277
2944
Fever
A03 [2002000144]
1.0e+00
1.3e+00
—
—
—
—
6.5e-01
cases:6.12%
controls:2.34%
cases:1.75%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.73%
controls:2.52%
21
80
322
3345
6
16
337
3409
—
—
—
—
14
76
282
2942
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
3.7e-02
1.7e-01
—
—
1.5e+00
9.7e-01
4.7e-01
cases:8.45%
controls:8.18%
cases:4.08%
controls:3.47%
—
—
—
—
cases:2.33%
controls:0.56%
cases:8.98%
controls:3.61%
cases:15.54%
controls:10.27%
29
280
314
3145
14
119
329
3306
—
—
8
19
335
3403
30
121
304
3234
46
310
250
2708
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
5.6e-01
7.3e-01
1.6e+00
—
1.4e+00
8.0e-01
9.7e-01
cases:9.91%
controls:5.93%
cases:5.25%
controls:2.60%
cases:2.04%
controls:0.44%
—
—
cases:2.04%
controls:0.53%
cases:5.99%
controls:2.77%
cases:17.91%
controls:7.65%
34
203
309
3222
18
89
325
3336
7
15
336
3410
—
7
18
336
3404
20
93
314
3262
53
231
243
2787
Asthma
J45 [45596282]
5.2e-01
—
—
—
—
—
9.6e-01
cases:3.50%
controls:2.10%
—
—
—
—
—
—
—
—
—
—
cases:6.08%
controls:2.42%
12
72
331
3353
—
—
—
—
—
18
73
278
2945
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
4.3e-01
9.4e-01
1.7e+00
—
—
6.3e-01
4.4e-01
cases:19.53%
controls:13.69%
cases:9.04%
controls:3.74%
cases:1.46%
controls:0.26%
—
—
—
—
cases:6.59%
controls:3.64%
cases:17.91%
controls:12.29%
67
469
276
2956
31
128
312
3297
5
9
338
3416
—
—
22
122
312
3233
53
371
243
2647
phenoxymethylpenicillin; oral
J01CE02 [21602842]
4.3e-01
9.4e-01
1.7e+00
—
—
6.3e-01
4.4e-01
cases:19.53%
controls:13.69%
cases:9.04%
controls:3.74%
cases:1.46%
controls:0.26%
—
—
—
—
cases:6.59%
controls:3.64%
cases:17.91%
controls:12.29%
67
469
276
2956
31
128
312
3297
5
9
338
3416
—
—
22
122
312
3233
53
371
243
2647
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
4.2e-01
7.3e-01
—
—
—
5.7e-01
9.2e-01
cases:6.41%
controls:4.32%
cases:2.92%
controls:1.43%
—
—
—
—
—
—
cases:2.40%
controls:1.37%
cases:8.45%
controls:3.55%
22
148
321
3277
10
49
333
3376
—
—
—
8
46
326
3309
25
107
271
2911
clarithromycin; oral, parenteral
J01FA09 [21602977]
9.2e-01
—
—
—
—
1.6e+00
6.5e-01
cases:7.00%
controls:2.92%
—
—
—
—
—
—
—
—
cases:1.50%
controls:0.30%
cases:3.38%
controls:1.79%
24
100
319
3325
—
—
—
—
5
10
329
3345
10
54
286
2964
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
5.8e-01
—
—
—
-1.0e+50
—
9.0e-01
cases:4.08%
controls:2.34%
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
cases:6.76%
controls:2.85%
14
80
329
3345
—
—
—
0
5
343
3417
—
20
86
276
2932
Cathetrisation of vein
TPH04 [2001309597]
-2.4e-01
—
—
—
—
1.0e+00
8.8e-01
cases:2.04%
controls:2.57%
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.86%
cases:6.76%
controls:2.92%
7
88
336
3337
—
—
—
—
8
29
326
3326
20
88
276
2930
Gastroenterology
10 [38004455]
-1.4e-01
4.3e-01
—
—
—
7.7e-01
8.6e-01
cases:4.96%
controls:5.64%
cases:4.08%
controls:2.69%
—
—
—
—
—
—
cases:5.09%
controls:2.41%
cases:13.51%
controls:6.20%
17
193
326
3232
14
92
329
3333
—
—
—
17
81
317
3274
40
187
256
2831
melatonin; oral
N05CH01 [21604659]
1.3e-01
2.8e-01
—
—
—
2.7e-01
8.5e-01
cases:2.33%
controls:2.04%
cases:1.46%
controls:1.11%
—
—
—
—
—
—
cases:1.80%
controls:1.37%
cases:7.43%
controls:3.31%
8
70
335
3355
5
38
338
3387
—
—
—
6
46
328
3309
22
100
274
2918
mometasone; nasal
R01AD09 [21605051]
4.6e-01
8.5e-01
—
—
—
6.1e-01
2.1e-01
cases:11.95%
controls:7.88%
cases:7.87%
controls:3.53%
—
—
—
—
—
—
cases:6.29%
controls:3.52%
cases:9.46%
controls:7.82%
41
270
302
3155
27
121
316
3304
—
—
—
21
118
313
3237
28
236
268
2782
mirtazapine; oral
N06AX11 [21604740]
3.7e-01
1.3e-01
—
—
—
4.2e-01
8.4e-01
cases:7.29%
controls:5.17%
cases:2.62%
controls:2.31%
—
—
—
—
—
—
cases:4.49%
controls:3.01%
cases:13.18%
controls:6.13%
25
177
318
3248
9
79
334
3346
—
—
—
15
101
319
3254
39
185
257
2833
amitriptyline; oral, parenteral
N06AA09 [21604696]
4.6e-01
7.8e-01
—
—
—
9.3e-01
8.3e-01
cases:6.12%
controls:3.97%
cases:3.50%
controls:1.64%
—
—
—
—
—
—
cases:3.89%
controls:1.58%
cases:9.12%
controls:4.17%
21
136
322
3289
12
56
331
3369
—
—
—
13
53
321
3302
27
126
269
2892
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
3.9e-01
—
-1.0e+50
—
-1.0e+50
6.6e-01
8.3e-01
cases:4.66%
controls:3.21%
—
—
cases:0.00%
controls:0.18%
—
—
cases:0.00%
controls:0.20%
cases:2.40%
controls:1.25%
cases:9.80%
controls:4.51%
16
110
327
3315
—
0
6
343
3419
—
0
7
343
3415
8
42
326
3313
29
136
267
2882
prednisolone; oral, parenteral
H02AB06 [21602734]
5.5e-01
5.5e-01
9.7e-01
—
—
8.2e-01
4.5e-01
cases:14.58%
controls:8.99%
cases:6.12%
controls:3.62%
cases:1.75%
controls:0.67%
—
—
—
—
cases:8.08%
controls:3.73%
cases:15.54%
controls:10.54%
50
308
293
3117
21
124
322
3301
6
23
337
3402
—
—
27
125
307
3230
46
318
250
2700
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
3.9e-01
4.1e-01
7.7e-01
—
1.1e+00
8.2e-01
3.5e-01
cases:13.99%
controls:9.90%
cases:8.16%
controls:5.58%
cases:1.75%
controls:0.82%
—
—
cases:2.33%
controls:0.79%
cases:11.38%
controls:5.37%
cases:21.28%
controls:16.04%
48
339
295
3086
28
191
315
3234
6
28
337
3397
—
8
27
335
3395
38
180
296
3175
63
484
233
2534
prednisolone
A07EA01 [21600653]
5.5e-01
5.4e-01
9.3e-01
—
—
8.1e-01
4.4e-01
cases:14.58%
controls:8.99%
cases:6.12%
controls:3.65%
cases:1.75%
controls:0.70%
—
—
—
—
cases:8.08%
controls:3.76%
cases:15.54%
controls:10.64%
50
308
293
3117
21
125
322
3300
6
24
337
3401
—
—
27
126
307
3229
46
321
250
2697
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.6e-01
6.5e-01
5.4e-01
—
7.9e-01
8.1e-01
4.4e-01
cases:11.95%
controls:8.67%
cases:9.33%
controls:5.08%
cases:1.75%
controls:1.02%
—
—
cases:2.92%
controls:1.34%
cases:11.98%
controls:5.69%
cases:19.26%
controls:13.35%
41
297
302
3128
32
174
311
3251
6
35
337
3390
—
10
46
333
3376
40
191
294
3164
57
403
239
2615
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
8.0e-01
6.1e-01
—
—
-1.0e+50
3.7e-01
4.4e-01
cases:8.45%
controls:3.97%
cases:2.92%
controls:1.61%
—
—
—
—
cases:0.00%
controls:0.18%
cases:2.69%
controls:1.88%
cases:9.46%
controls:6.33%
29
136
314
3289
10
55
333
3370
—
—
0
6
343
3416
9
63
325
3292
28
191
268
2827
enoxaparin; parenteral
B01AB05 [21600976]
4.9e-02
—
—
—
—
6.9e-01
7.8e-01
cases:4.96%
controls:4.73%
—
—
—
—
—
—
—
—
cases:2.69%
controls:1.37%
cases:8.45%
controls:4.04%
17
162
326
3263
—
—
—
—
9
46
325
3309
25
122
271
2896
azithromycin; oral, parenteral
J01FA10 [21602978]
3.3e-01
3.0e-01
—
—
—
8.6e-01
7.5e-01
cases:11.37%
controls:8.47%
cases:3.21%
controls:2.39%
—
—
—
—
—
—
cases:4.79%
controls:2.09%
cases:12.16%
controls:6.13%
39
290
304
3135
11
82
332
3343
—
—
—
16
70
318
3285
36
185
260
2833
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.1e-01
5.1e-01
6.5e-01
—
5.7e-01
7.5e-01
4.5e-01
cases:21.87%
controls:15.71%
cases:14.29%
controls:9.11%
cases:3.79%
controls:2.01%
—
—
cases:2.92%
controls:1.67%
cases:16.17%
controls:8.35%
cases:25.68%
controls:18.06%
75
538
268
2887
49
312
294
3113
13
69
330
3356
—
10
57
333
3365
54
280
280
3075
76
545
220
2473
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
3.5e-01
—
—
—
-1.0e+50
-2.3e-01
7.5e-01
cases:6.41%
controls:4.61%
—
—
—
—
—
—
cases:0.00%
controls:0.15%
cases:1.50%
controls:1.88%
cases:9.12%
controls:4.54%
22
158
321
3267
—
—
—
0
5
343
3417
5
63
329
3292
27
137
269
2881
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.6e-01
1.3e-01
—
—
—
8.1e-01
7.4e-01
cases:7.00%
controls:4.55%
cases:3.21%
controls:2.83%
—
—
—
—
—
—
cases:5.69%
controls:2.62%
cases:15.54%
controls:8.08%
24
156
319
3269
11
97
332
3328
—
—
—
19
88
315
3267
46
244
250
2774
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
5.3e-01
5.9e-01
2.1e+00
—
—
6.3e-01
7.4e-01
cases:12.24%
controls:7.62%
cases:4.08%
controls:2.31%
cases:1.46%
controls:0.18%
—
—
—
—
cases:3.59%
controls:1.94%
cases:13.51%
controls:6.96%
42
261
301
3164
14
79
329
3346
5
6
338
3419
—
—
12
65
322
3290
40
210
256
2808
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.4e-01
1.1e-01
5.8e-01
—
1.1e+00
7.3e-01
4.5e-01
cases:18.95%
controls:14.31%
cases:8.16%
controls:7.36%
cases:1.46%
controls:0.82%
—
—
cases:3.50%
controls:1.20%
cases:15.27%
controls:7.96%
cases:29.05%
controls:20.71%
65
490
278
2935
28
252
315
3173
5
28
338
3397
—
12
41
331
3381
51
267
283
3088
86
625
210
2393
General Practice
1 [38004446]
1.6e-01
6.4e-01
9.7e-01
—
—
7.3e-01
4.0e-01
cases:12.24%
controls:10.66%
cases:7.87%
controls:4.29%
cases:1.46%
controls:0.55%
—
—
—
—
cases:8.98%
controls:4.56%
cases:18.92%
controls:13.52%
42
365
301
3060
27
147
316
3278
5
19
338
3406
—
—
30
153
304
3202
56
408
240
2610
Person consulting for explanation of investigation findings
Z71.2 [45552100]
4.1e-01
4.0e-01
—
—
2.1e+00
5.8e-01
7.2e-01
cases:5.25%
controls:3.53%
cases:2.62%
controls:1.78%
—
—
—
—
cases:1.46%
controls:0.18%
cases:2.69%
controls:1.52%
cases:10.47%
controls:5.37%
18
121
325
3304
9
61
334
3364
—
—
5
6
338
3416
9
51
325
3304
31
162
265
2856
oxazepam; oral
N05BA04 [21604569]
4.6e-01
4.1e-01
1.0e+00
—
—
6.2e-01
7.1e-01
cases:7.00%
controls:4.55%
cases:4.08%
controls:2.74%
cases:2.04%
controls:0.73%
—
—
—
—
cases:5.09%
controls:2.80%
cases:10.14%
controls:5.27%
24
156
319
3269
14
94
329
3331
7
25
336
3400
—
—
17
94
317
3261
30
159
266
2859
Caries of dentine
K02.1 [45548134]
2.2e-01
6.9e-01
—
—
1.2e+00
1.3e-01
2.4e-01
cases:17.78%
controls:14.77%
cases:11.08%
controls:5.87%
—
—
—
—
cases:2.92%
controls:0.91%
cases:7.49%
controls:6.62%
cases:21.96%
controls:18.16%
61
506
282
2919
38
201
305
3224
—
—
10
31
333
3391
25
222
309
3133
65
548
231
2470
Psychiatry
26 [38004469]
6.7e-01
7.0e-01
3.0e-01
—
1.1e+00
4.0e-01
6.4e-01
cases:10.79%
controls:5.81%
cases:5.83%
controls:2.98%
cases:1.46%
controls:1.08%
—
—
cases:2.92%
controls:1.02%
cases:4.49%
controls:3.07%
cases:10.47%
controls:5.80%
37
199
306
3226
20
102
323
3323
5
37
338
3388
—
10
35
333
3387
15
103
319
3252
31
175
265
2843
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
1.2e-01
3.6e-01
8.9e-01
—
7.0e-01
6.5e-01
2.7e-01
cases:14.87%
controls:13.40%
cases:9.04%
controls:6.48%
cases:2.04%
controls:0.85%
—
—
cases:2.33%
controls:1.17%
cases:13.47%
controls:7.51%
cases:23.99%
controls:19.45%
51
459
292
2966
31
222
312
3203
7
29
336
3396
—
8
40
335
3382
45
252
289
3103
71
587
225
2431
Essential (primary) hypertension
I10 [45591453]
8.2e-02
3.8e-01
1.0e+00
—
7.3e-01
6.4e-01
3.0e-01
cases:15.16%
controls:14.13%
cases:11.08%
controls:7.85%
cases:3.79%
controls:1.37%
—
—
cases:2.33%
controls:1.14%
cases:13.17%
controls:7.39%
cases:25.68%
controls:20.44%
52
484
291
2941
38
269
305
3156
13
47
330
3378
—
8
39
335
3383
44
248
290
3107
76
617
220
2401
Pain in limb
M79.6 [45587063]
3.3e-01
3.0e-01
—
—
—
-4.0e-02
6.3e-01
cases:7.29%
controls:5.34%
cases:2.62%
controls:1.96%
—
—
—
—
—
—
cases:2.69%
controls:2.80%
cases:15.20%
controls:8.71%
25
183
318
3242
9
67
334
3358
—
—
—
9
94
325
3261
45
263
251
2755
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.0e-01
4.5e-01
1.0e+00
—
6.9e-01
5.7e-01
6.2e-01
cases:11.95%
controls:9.17%
cases:9.33%
controls:6.16%
cases:3.50%
controls:1.28%
—
—
cases:2.92%
controls:1.49%
cases:10.78%
controls:6.38%
cases:24.66%
controls:14.91%
41
314
302
3111
32
211
311
3214
12
44
331
3381
—
10
51
333
3371
36
214
298
3141
73
450
223
2568
Upper gastrointestinal surgery
106 [44777669]
1.7e-01
7.7e-01
—
—
7.4e-01
5.3e-01
6.2e-01
cases:9.91%
controls:8.50%
cases:6.41%
controls:3.07%
—
—
—
—
cases:1.46%
controls:0.70%
cases:5.99%
controls:3.61%
cases:16.55%
controls:9.64%
34
291
309
3134
22
105
321
3320
—
—
5
24
338
3398
20
121
314
3234
49
291
247
2727
Eosinophils [#/volume] in Blood
26449-9 [3013115]
3.3e-01
4.7e-01
1.0e+00
—
7.4e-01
6.2e-01
6.2e-01
cases:12.54%
controls:9.31%
cases:9.62%
controls:6.22%
cases:3.79%
controls:1.37%
—
—
cases:3.21%
controls:1.55%
cases:11.38%
controls:6.44%
cases:23.99%
controls:14.55%
43
319
300
3106
33
213
310
3212
13
47
330
3378
—
11
53
332
3369
38
216
296
3139
71
439
225
2579
Orthopedic Surgery
20 [38004465]
2.5e-01
2.7e-01
7.4e-01
—
1.3e+00
4.3e-01
6.1e-01
cases:15.74%
controls:12.70%
cases:6.41%
controls:4.96%
cases:1.46%
controls:0.70%
—
—
cases:2.33%
controls:0.64%
cases:7.49%
controls:4.98%
cases:23.99%
controls:14.58%
54
435
289
2990
22
170
321
3255
5
24
338
3401
—
8
22
335
3400
25
167
309
3188
71
440
225
2578
salbutamol; inhalant
R03AC02 [21603256]
5.1e-01
3.1e-01
8.9e-01
—
9.9e-01
4.2e-01
3.8e-01
cases:20.41%
controls:13.31%
cases:9.04%
controls:6.77%
cases:2.04%
controls:0.85%
—
—
cases:2.62%
controls:0.99%
cases:10.48%
controls:7.15%
cases:21.96%
controls:16.07%
70
456
273
2969
31
232
312
3193
7
29
336
3396
—
9
34
334
3388
35
240
299
3115
65
485
231
2533
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.3e-01
3.3e-01
8.9e-01
—
1.0e+00
1.5e-01
4.3e-01
cases:27.41%
controls:23.09%
cases:18.66%
controls:14.13%
cases:4.08%
controls:1.72%
—
—
cases:3.50%
controls:1.32%
cases:17.96%
controls:15.80%
cases:47.30%
controls:36.91%
94
791
249
2634
64
484
279
2941
14
59
329
3366
—
12
45
331
3377
60
530
274
2825
140
1114
156
1904
glucosamine; oral
M01AX05 [21604002]
6.7e-01
—
—
—
-1.0e+50
6.0e-01
4.8e-01
cases:5.25%
controls:2.74%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:2.10%
controls:1.16%
cases:6.08%
controls:3.84%
18
94
325
3331
—
—
—
0
7
343
3415
7
39
327
3316
18
116
278
2902
Restricted health certificate
SPAT1283 [2001700384]
4.4e-01
—
—
—
—
7.5e-01
3.7e-01
cases:4.96%
controls:3.24%
—
—
—
—
—
—
—
—
cases:1.50%
controls:0.72%
cases:4.05%
controls:2.85%
17
111
326
3314
—
—
—
—
5
24
329
3331
12
86
284
2932
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
0
11
343
3414
0
11
343
3414
—
—
—
0
6
334
3349
—
semaglutide; oral, parenteral
A10BJ06 [1501778]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
8.9e-01
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.29%
—
—
cases:4.39%
controls:1.86%
—
0
20
343
3405
0
8
343
3417
—
0
10
343
3412
—
13
56
283
2962
Other ultrasound examination during pregnancy
SPAT1189 [2001700290]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
cases:0.00%
controls:0.30%
—
—
—
—
—
0
5
334
3350
0
9
296
3009
Support of social functional capacity
SPAT1234 [2001700335]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
343
3417
0
11
334
3344
—
celecoxib
L01XX33 [21603805]
-8.0e-02
—
—
—
—
—
8.6e-01
cases:1.46%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
cases:3.38%
controls:1.46%
5
54
338
3371
—
—
—
—
—
10
44
286
2974
Benign neoplasm: Stomach
D13.1 [45586087]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
0
8
343
3417
0
5
343
3420
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
4.2e-01
6.5e-01
8.4e-01
—
7.3e-01
4.8e-01
4.0e-01
cases:9.33%
controls:6.31%
cases:7.58%
controls:4.12%
cases:1.75%
controls:0.76%
—
—
cases:1.75%
controls:0.85%
cases:7.19%
controls:4.56%
cases:18.24%
controls:13.02%
32
216
311
3209
26
141
317
3284
6
26
337
3399
—
6
29
337
3393
24
153
310
3202
54
393
242
2625
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
—
—
—
—
—
—
8.3e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.69%
controls:1.56%
—
—
—
—
—
—
5
47
291
2971
Percutaneous gastrostomy
JDB10 [2001304713]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.00%
—
—
—
—
—
—
—
—
6
0
337
3422
—
—
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
1.2e+00
—
—
—
—
—
5.9e-01
cases:2.92%
controls:0.93%
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:1.33%
10
32
333
3393
—
—
—
—
—
7
40
289
2978
Struck by thrown, projected or falling object(s)
W20 [45756258]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
296
3013
Apolipoprotein B/Apolipoprotein A-I [Percentile]
9340-1 [3011831]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
0
5
334
3350
—
tropicamide
S01FA06 [21605065]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
0
6
343
3419
—
—
—
—
—
celecoxib; oral
M01AH01 [21603992]
-8.0e-02
—
—
—
—
—
8.6e-01
cases:1.46%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
cases:3.38%
controls:1.46%
5
54
338
3371
—
—
—
—
—
10
44
286
2974
Spinal stenosis
M48.0 [45557888]
-9.8e-02
4.8e-01
-1.0e+50
—
—
—
7.3e-01
cases:1.46%
controls:1.61%
cases:1.46%
controls:0.91%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
cases:3.38%
controls:1.66%
5
55
338
3370
5
31
338
3394
0
5
343
3420
—
—
—
10
50
286
2968
Other and unspecified infectious diseases
B99 [45590874]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
296
3013
General Surgery
2 [38004447]
3.0e-01
5.8e-01
—
—
—
6.3e-01
1.4e-01
cases:19.53%
controls:15.24%
cases:7.29%
controls:4.20%
—
—
—
—
—
—
cases:8.38%
controls:4.65%
cases:15.20%
controls:13.52%
67
522
276
2903
25
144
318
3281
—
—
—
28
156
306
3199
45
408
251
2610
scopolamine
S01FA02 [21605061]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
—
Other and unspecified ovarian cysts
N83.2 [45539066]
9.7e-01
—
—
—
—
—
—
cases:1.75%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
6
23
337
3402
—
—
—
—
—
—
ticagrelor; oral
B01AC24 [40252640]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.26%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.53%
0
9
343
3416
0
6
343
3419
—
—
—
0
8
334
3347
0
16
296
3002
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
—
—
—
—
—
—
2.0e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:2.65%
—
—
—
—
—
—
8
80
288
2938
Vacuum aspiration of products of conception from uterus
LCH00 [2001306620]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
7
296
3011
Coagulation factor IX activity actual/normal in Platelet poor plasma by Coagulation assay
3187-2 [3006109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
343
3419
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
-9.5e-02
2.2e-01
—
—
—
-2.2e-02
2.5e-01
cases:16.33%
controls:17.66%
cases:7.29%
controls:5.93%
—
—
—
—
—
—
cases:5.99%
controls:6.11%
cases:27.36%
controls:22.63%
56
605
287
2820
25
203
318
3222
—
—
—
20
205
314
3150
81
683
215
2335
Cytoplasmic Ig cells/cells in Blood
17219-7 [3034092]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
—
Removal of internal fixation device from ankle or foot
NHU20 [2001308384]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
343
3418
—
—
—
—
—
—
Inflammation of eyelid, unspecified
H01.9 [45557271]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
343
3419
—
—
—
—
—
—
Adjustment and management of cardiac devices
Z45.0 [45595515]
1.4e+00
—
—
—
—
—
—
cases:1.46%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
5
12
338
3413
—
—
—
—
—
—
Lumbar epidural anesthesia
WX306 [2001310796]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
8
334
3347
—
Emotionally unstable personality disorder, impulsive
F60.30 [2000502022]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
8
296
3010
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
24
334
3331
—
Morphology [Interpretation] in Blood Narrative
18314-5 [3000093]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
343
3419
—
—
—
—
—
—
Smith extractable nuclear Ab [Presence] in Serum by Immunoblot
56730-5 [40759849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
—
Tumor of uncertain or unknown nature in the ovary without histology
D39.10 [2000501354]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
7
296
3011
Hyperlipidaemia, unspecified
E78.5 [45537986]
—
—
—
—
-1.0e+50
—
9.6e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
cases:3.72%
controls:1.46%
—
—
—
—
0
6
343
3416
—
11
44
285
2974
follitropin beta; parenteral
G03GA06 [21602604]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
7
296
3011
Other abnormal function of teeth and jaws
K07.58 [2000502789]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
296
3012
Conductive hearing loss, unilateral with unrestricted hearing on the contralateral side
H90.1 [45567150]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
—
Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
8
334
3347
—
Acute maxillary sinusitis
J01.0 [45601112]
2.2e-01
—
—
—
—
6.0e-01
3.9e-01
cases:4.08%
controls:3.30%
—
—
—
—
—
—
—
—
cases:2.10%
controls:1.16%
cases:5.07%
controls:3.48%
14
113
329
3312
—
—
—
—
7
39
327
3316
15
105
281
2913
Ultrasound screening of fetal nuchal translucency
MA2JE [2001306837]
1.3e+00
—
—
—
—
—
—
cases:2.92%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
10
29
333
3396
—
—
—
—
—
—
Sequelae of subarachnoid haemorrhage
I69.0 [45543193]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
—
Left bundle-branch block, unspecified
I44.7 [45586583]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
8
296
3010
Wedge excision of mammary gland
HAB40 [2001303928]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
12
343
3413
—
—
—
—
—
0
7
296
3011
Geriatric Medicine
38 [38004478]
—
—
—
—
—
-1.0e+50
4.7e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:1.69%
controls:1.06%
—
—
—
—
—
0
7
334
3348
5
32
291
2986
Weakness/tiredness general
A04 [2002000145]
4.0e-01
—
—
—
—
—
6.5e-01
cases:2.04%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:2.35%
7
47
336
3378
—
—
—
—
—
13
71
283
2947
Tympanometry
SPAT1044 [2001700145]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
14
343
3411
0
5
343
3420
—
—
—
—
0
10
296
3008
Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]
4.0e-01
—
—
—
—
—
2.7e-01
cases:2.04%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:1.69%
controls:1.29%
7
47
336
3378
—
—
—
—
—
5
39
291
2979
metronidazole; vaginal
G01AF01 [21602392]
5.0e-01
—
—
—
—
—
1.5e-01
cases:3.50%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:1.76%
12
74
331
3351
—
—
—
—
—
6
53
290
2965
Atrioventricular block, second degree
I44.1 [45543177]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
0
5
343
3420
—
—
—
—
—
0
5
296
3013
sodium picosulfate; oral
A06AB08 [21600545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
343
3419
—
—
—
—
—
—
itraconazole; oral, parenteral
J02AC02 [21603081]
1.3e-01
—
—
—
—
—
—
cases:1.46%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
5
44
338
3381
—
—
—
—
—
—
Acute stress reaction mild
F43.00 [2000501998]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
8
296
3010
Insulin glargine 300 U / ml
177 [2001600176]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
11
296
3007
Sinusitis acute/chronic
R75 [2002000943]
1.0e+00
—
—
—
—
—
—
cases:1.46%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
338
3407
—
—
—
—
—
—
olmesartan medoxomil and diuretics
C09DA08 [21601840]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
—
Vertigo/dizziness
N17 [2002000728]
6.1e-02
—
—
—
—
—
3.3e-01
cases:1.46%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:1.95%
5
47
338
3378
—
—
—
—
—
8
59
288
2959
Hyperkalaemia
E87.5 [45537990]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
296
3012
Menopausal and female climacteric states
N95.1 [45548683]
—
—
—
—
—
—
4.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.36%
controls:1.52%
—
—
—
—
—
—
7
46
289
2972
Supervision of normal first pregnancy
Z34.0 [45595500]
4.4e-01
—
—
—
—
—
—
cases:1.75%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
—
6
39
337
3386
—
—
—
—
—
—
levocabastine
S01GX02 [21605086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
343
3406
—
—
—
—
—
—
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
4.0e-02
—
—
—
-1.0e+50
—
8.5e-01
cases:1.46%
controls:1.40%
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
cases:4.39%
controls:1.92%
5
48
338
3377
—
—
—
0
9
343
3413
—
13
58
283
2960
Deep bite
K07.23 [2000502769]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
296
3013
Cardiac murmur, unspecified
R01.1 [45548943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
7
296
3011
Colonoscopy Study observation
28023-0 [3022145]
—
—
—
—
—
—
4.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:2.75%
—
—
—
—
—
—
13
83
283
2935
Neutrophils [#/volume] in Blood
26499-4 [3017732]
8.4e-01
—
—
—
—
—
3.0e-01
cases:1.75%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
cases:3.72%
controls:2.78%
6
26
337
3399
—
—
—
—
—
11
84
285
2934
Benign neoplasm: Skin of trunk
D23.5 [45581294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
8
296
3010
Postsurgical hypothyroidism
E89.01 [2000501554]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
8
296
3010
acitretin; oral
D05BB02 [21602051]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
8
296
3010
Health check-up of pregnant person
SPAT1379 [2001700479]
3.1e-01
—
-1.0e+50
—
-1.0e+50
—
-4.0e-02
cases:2.33%
controls:1.72%
—
—
cases:0.00%
controls:0.29%
—
—
cases:0.00%
controls:0.23%
—
—
cases:1.69%
controls:1.76%
8
59
335
3366
—
0
10
343
3415
—
0
8
343
3414
—
5
53
291
2965
Nutritional guidance related to treatment and rehabilitation for medical condition
OAB74 [2001308652]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
296
3013
Gas panel - Venous blood
24339-4 [3000991]
8.3e-01
—
—
—
—
—
3.6e-01
cases:1.46%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:3.38%
controls:2.39%
5
22
338
3403
—
—
—
—
—
10
72
286
2946
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
9.7e-01
—
—
—
—
—
9.1e-02
cases:1.75%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:3.04%
controls:2.78%
6
23
337
3402
—
—
—
—
—
9
84
287
2934
Insulin-dependent diabetes mellitus - Diabetic retinopathy
H36.09*E10.3 [2000502327]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:0.00%
controls:0.18%
cases:0.00%
controls:0.23%
—
0
7
343
3418
—
—
—
0
6
334
3349
0
7
296
3011
Primary coxarthrosis, bilateral
M16.0 [45543482]
—
-1.0e+50
—
—
—
-1.0e+50
6.1e-01
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:1.69%
controls:0.93%
—
0
13
343
3412
—
—
—
0
11
334
3344
5
28
291
2990
dexamethasone
S02BA06 [21605168]
5.4e-01
—
—
—
—
—
4.9e-01
cases:1.75%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:3.38%
controls:2.09%
6
35
337
3390
—
—
—
—
—
10
63
286
2955
capecitabine
L01BC06 [21601440]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
0
11
343
3414
—
—
—
—
0
6
334
3349
—
Hepatitis E virus IgM Ab [Presence] in Serum
14212-5 [3002222]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
296
3012
xylometazoline; nasal
R01AA07 [21605016]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
343
3417
—
—
—
—
—
—
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
22
343
3403
0
11
343
3414
—
—
—
0
10
334
3345
—
Ulcerative (chronic) rectosigmoiditis
K51.3 [45533603]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
0
8
343
3417
0
5
343
3420
—
—
—
—
—
Removal of sutures from oral mucosa
SXB00 [2001310580]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
0
8
343
3417
—
—
—
0
5
334
3350
—
Fear of urinary disease other
U27 [2002001147]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
296
3012
Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
0
6
334
3349
—
Lactate [Moles/volume] in Blood
32693-4 [3047181]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.69%
controls:0.46%
—
—
—
—
—
—
5
14
291
3004
Dermatitis, unspecified
L30.9 [45572271]
-1.6e-01
—
—
—
—
1.1e+00
6.6e-01
cases:1.75%
controls:2.04%
—
—
—
—
—
—
—
—
cases:2.10%
controls:0.72%
cases:6.08%
controls:3.25%
6
70
337
3355
—
—
—
—
7
24
327
3331
18
98
278
2920
Partial resection of small intestine
JFB00 [2001304885]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
343
3417
—
—
—
—
—
—
Gradual caries removal, one tooth surface
SFD10 [2001310372]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
296
3013
Sick sinus syndrome
I49.5 [45562354]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
0
5
343
3420
—
—
—
0
7
334
3348
—
Overall malignant tumor of the mammary gland, ductal tumor
C50.81 [2000501014]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
Need for immunization against influenza
Z25.1 [45581017]
—
—
—
—
—
—
1.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.69%
controls:1.42%
—
—
—
—
—
—
5
43
291
2975
Initiation and monitoring of IV fluid therapy
SPAT1083 [2001700184]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
0
8
343
3417
—
—
—
0
6
334
3349
—
Relationship problem with partner
Z12 [2002001468]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
0
5
343
3420
—
—
—
—
—
Other specified noninfective gastroenteritis and colitis
K52.88 [2000502923]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
10
296
3008
Hemorrhoidectomy
JHB00 [2001305139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
11
296
3007
Presbyacusis
H84 [2002000539]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
343
3417
—
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
4.5e-01
—
—
—
—
1.1e+00
7.9e-01
cases:2.62%
controls:1.69%
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.83%
cases:5.74%
controls:2.68%
9
58
334
3367
—
—
—
—
8
28
326
3327
17
81
279
2937
Posterior interbody fusion of lumbar spine, 2 vertebrae
NAG66 [2001307126]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
343
3419
—
—
—
—
—
—
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
N04BA03 [21604466]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
296
3013
Hip X-ray examination
NF1AA [2001307894]
—
-1.0e+50
—
—
—
—
1.1e+00
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.66%
—
0
6
343
3419
—
—
—
—
6
20
290
2998
Leiomyoma of uterus, unspecified
D25.9 [45542693]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
0
13
343
3412
—
—
—
0
7
334
3348
—
Other partial excision of mammary gland
HAB99 [2001303930]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
5
343
3420
—
—
—
—
—
0
8
296
3010
fluvastatin; oral
C10AA04 [21601859]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
0
11
343
3411
—
—
naproxen and esomeprazole; oral
M01AE52 [40254096]
1.9e-01
—
—
—
-1.0e+50
—
—
cases:2.62%
controls:2.19%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
9
75
334
3350
—
—
—
0
7
343
3415
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
209
1256
2.66
17.53
2.6
2.1
—
—
—
0
0
62
274
2.54
9.11
1.5
1.4
—
—
—
0
0
192
1353
1.93
8.31
6.0
5.1
35.78
35.96
g/l
0.16
184
1289
157
1048
1.91
7.88
6.1
6.1
—
—
—
0
0
201
1503
1.80
6.60
2.9
2.8
—
—
estimate
—
0
0
285
2382
2.09
6.57
9.5
8.4
78.61
78.99
u/l
0.06
275
2249
233
1835
1.82
6.29
6.3
5.3
6.62
6.58
mmol/l
0.13
222
1722
229
1797
1.80
6.22
10.2
10.3
4.23
4.04
e9/l
0.70
193
1574
211
1621
1.77
6.12
6.1
6.2
0.58
0.57
e9/l
0.33
176
1391
211
1628
1.75
5.96
6.2
6.3
0.04
0.04
e9/l
0.40
175
1394
285
2410
2.01
5.94
5.1
4.3
14.72
14.72
pmol/l
0.01
264
2206
201
1536
1.73
5.82
9.3
7.7
1.21
1.21
mmol/l
0.37
176
1336
67
367
2.02
5.79
2.2
1.7
—
—
—
0
0
215
1681
1.73
5.67
6.8
6.5
0.21
0.19
e9/l
0.77
187
1473
41
186
2.37
5.65
3.8
4.1
4.69
4.64
pmol/l
0.11
35
165
188
1418
1.71
5.64
18.0
11.7
1.27
1.20
inr
0.92
156
1169
212
1664
1.70
5.39
6.2
6.3
1.91
1.97
e9/l
0.17
184
1472
33
139
2.52
5.33
1.2
1.3
—
—
—
0
0
195
1500
1.68
5.32
6.5
6.3
2.71
2.81
%
0.25
183
1423
195
1500
1.68
5.32
6.5
6.5
8.66
8.76
%
0.22
182
1427
194
1496
1.67
5.20
6.6
6.4
0.69
0.69
%
0.04
182
1413
198
1536
1.67
5.17
6.4
6.4
26.47
27.90
%
1.04
186
1473
147
1065
1.66
4.94
4.0
3.5
2.35
2.35
mmol/l
0.10
135
972
331
3025
2.93
4.86
23.1
15.9
21.22
23.54
mg/l
0.81
297
2487
134
952
1.66
4.84
5.5
4.3
7.41
7.40
ph
1.74
96
672
57
316
1.96
4.73
2.5
2.5
38.06
33.48
u/l
0.26
47
260
176
1348
1.62
4.66
2.3
2.1
92.87
96.65
pmol/l
0.61
92
707
143
1050
1.61
4.45
2.8
2.4
—
—
—
0
0
191
1513
1.58
4.25
6.3
6.3
59.54
57.35
%
1.92
182
1458
75
470
1.76
4.23
1.9
1.9
29.75
29.19
s
0.42
70
460
178
1395
1.56
4.09
8.2
7.0
1.22
1.21
mmol/l
0.30
169
1293
103
712
1.63
4.02
1.9
1.7
1.95
1.27
mg/l
0.57
81
575
315
2857
2.08
4.02
6.5
5.3
1.91
1.88
mu/l
0.13
299
2631
131
967
1.57
3.86
1.5
1.5
—
—
—
0
0
87
586
1.65
3.73
3.0
2.9
506.69
529.55
mosm/kgh2o
0.42
72
512
138
1038
1.55
3.71
3.3
3.3
21.04
111.56
e6/l
0.80
106
779
148
1134
1.53
3.64
3.8
3.3
28.68
32.43
u/l
1.00
139
1078
46
260
1.89
3.61
5.1
2.6
66.82
66.77
g/l
0.02
46
243
176
1402
1.52
3.60
2.4
2.5
76.44
76.33
nmol/l
0.02
156
1267
39
209
1.98
3.57
3.1
2.1
—
—
—
0
0
330
3074
2.42
3.48
25.7
18.2
139.53
139.77
mmol/l
1.05
325
3019
250
2156
1.57
3.46
4.7
4.0
—
0.00
—
0
7
121
897
1.53
3.43
3.3
3.1
0.59
0.36
e6/l
0.45
86
635
330
3077
2.40
3.42
26.1
18.3
3.93
3.97
mmol/l
2.24
324
3017
64
409
1.69
3.34
1.3
1.3
—
—
—
0
0
67
436
1.66
3.26
1.4
1.2
—
—
—
0
0
125
955
1.48
3.00
2.2
2.2
170.14
261.06
u/l
0.65
114
911
114
855
1.50
2.99
5.1
4.6
—
—
—
0
0
96
696
1.52
2.96
2.7
2.7
5.48
5.12
e6/l
0.11
84
632
149
1183
1.45
2.92
4.1
4.0
79.01
74.20
e6/l
0.05
109
814
172
1405
1.44
2.88
13.1
11.5
0.00
0.00
e9/l
1.28
132
1146
85
607
1.53
2.79
4.0
3.6
125.34
330.17
ng/l
0.97
63
453
331
3123
2.23
2.75
19.0
13.7
—
—
—
0
0
26
133
2.03
2.73
2.4
2.3
—
—
—
0
0
64
431
1.59
2.71
7.5
7.6
103.70
104.21
mmol/l
0.34
64
431
75
526
1.54
2.67
3.5
2.4
14.26
13.46
umol/l
0.38
67
490
23
114
2.09
2.63
1.7
1.5
7.16
11.21
u/ml
—
5
18
245
2162
1.45
2.55
3.8
3.3
50.92
48.36
u/l
0.22
236
2054
80
579
1.50
2.45
1.8
1.8
—
—
—
0
0
117
912
1.43
2.44
3.6
3.2
1129.16
1192.42
ng/l
0.06
102
763
32
184
1.81
2.42
9.2
11.2
15.89
15.77
%
0.10
32
177
18
84
2.21
2.39
2.1
2.0
4.50
5.70
iu/l
—
8
36
14
59
2.43
2.32
3.6
2.4
—
—
—
0
0
16
72
2.28
2.31
1.3
1.6
—
—
—
0
0
179
1515
1.37
2.26
3.9
3.0
135.52
120.56
ug/l
0.30
164
1419
68
484
1.50
2.25
3.6
2.4
2.34
2.29
g/l
0.36
61
450
11
41
2.74
2.22
1.8
1.4
100.57
0.52
nmol/l
0.47
11
36
37
229
1.69
2.19
1.9
2.5
4.79
5.90
ug/l
0.25
27
210
194
1671
1.36
2.15
4.5
3.7
0.00
0.00
estimate
-0.00
50
340
334
3193
2.14
2.14
14.9
12.1
27.60
26.67
u/l
0.43
325
3108
306
2856
1.59
2.13
6.9
6.2
39.66
39.08
mmol/mol
0.54
287
2692
160
1339
1.36
2.13
4.0
3.4
6.31
6.20
ph
0.54
86
742
36
224
1.68
2.10
1.2
1.2
84.14
141.35
u/ml
—
7
79
19
96
2.04
2.09
3.5
2.5
1.34
1.48
mg/l
0.39
19
85
195
1686
1.36
2.09
4.5
3.7
0.00
0.00
estimate
-0.00
51
346
69
501
1.47
2.07
1.9
1.6
1406.91
1219.05
nmol/l
0.77
46
378
59
415
1.51
2.07
2.0
1.5
—
—
—
0
0
60
424
1.50
2.06
1.9
1.7
—
—
—
0
0
11
44
2.55
2.03
1.1
1.2
—
—
—
0
0
9
32
2.86
2.01
1.9
1.3
—
—
nmol/l
—
0
0
80
602
1.43
1.99
3.6
2.8
2.44
2.45
mmol/l
0.29
71
543
196
1703
1.35
1.99
4.7
3.7
0.00
0.93
estimate
0.50
48
323
159
1342
1.34
1.95
2.0
2.0
1.53
1.36
mmol/l
1.11
130
1139
18
92
2.01
1.94
1.0
1.2
—
—
—
0
0
127
1041
1.35
1.88
3.0
2.6
58.66
65.99
u/l
0.54
117
964
46
313
1.54
1.88
8.1
10.6
122.26
121.03
g/l
0.15
46
307
9
34
2.69
1.88
1.6
1.3
—
—
—
0
0
41
272
1.58
1.87
4.7
4.9
0.08
0.14
%
0.26
12
70
116
939
1.35
1.86
6.3
6.6
—
—
—
0
0
63
460
1.45
1.84
2.3
2.2
—
—
—
0
0
6
17
3.57
1.84
5.2
2.7
0.50
0.82
index
—
6
17
41
275
1.56
1.79
9.4
9.8
—
—
—
0
0
43
292
1.54
1.78
4.7
4.7
1.00
0.87
%
0.14
13
91
143
1201
1.32
1.78
5.2
3.8
19.63
38.59
ng/l
3.05
95
833
61
449
1.43
1.71
3.7
2.4
23.50
23.35
%
0.03
55
423
310
2930
1.53
1.71
5.7
5.0
6.03
5.90
mmol/l
0.91
287
2715
41
279
1.53
1.69
2.8
2.6
71.48
72.85
e9/l
0.08
30
205
16
83
1.97
1.67
4.6
3.1
4.20
1.84
index
—
10
50
68
513
1.40
1.67
3.1
3.1
2.15
2.25
e6/l
0.03
32
234
8
31
2.62
1.67
1.9
1.0
—
—
—
0
0
21
120
1.80
1.66
1.6
1.3
—
—
—
0
0
40
272
1.53
1.66
4.7
4.6
0.55
0.53
%
0.01
11
76
20
113
1.82
1.64
4.7
9.1
0.74
0.91
%
1.94
20
104
23
136
1.74
1.63
4.5
3.3
—
—
—
0
0
87
687
1.36
1.62
2.2
2.0
—
—
—
0
0
113
930
1.32
1.59
3.7
3.1
0.00
0.10
estimate
0.55
42
282
6
20
3.03
1.58
1.0
1.9
—
—
—
0
0
8
33
2.46
1.54
1.3
1.3
13.13
23.15
ng/l
—
8
33
18
101
1.82
1.52
2.7
3.2
9.04
2.32
ratio
—
9
53
46
329
1.46
1.51
8.5
10.3
95.68
95.59
%
0.04
46
322
62
469
1.39
1.50
1.3
1.4
667.50
527.20
titre
0.18
16
100
49
357
1.43
1.46
8.3
9.9
0.55
0.83
mmol/l
0.20
49
313
19
110
1.77
1.46
2.7
3.4
56.94
103.26
mg/l
0.39
14
94
26
165
1.62
1.45
1.3
1.3
—
—
—
0
0
49
359
1.42
1.42
8.4
9.8
7.41
7.42
ph
0.10
19
195
338
3283
2.03
1.41
33.4
24.1
7.04
6.69
e9/l
1.98
332
3222
338
3283
2.03
1.41
33.3
24.0
4.47
4.50
e12/l
0.43
331
3222
93
760
1.31
1.36
4.1
5.0
—
—
—
0
0
44
319
1.43
1.36
2.5
4.7
3.92
21.67
ug/l
0.71
33
257
9
42
2.17
1.34
4.0
2.2
29.67
32.43
pg
—
9
42
11
54
2.07
1.34
2.8
3.1
3.26
4.43
e9/l
1.92
11
54
24
153
1.61
1.33
1.3
1.3
27.32
22.10
iu/l
0.27
19
131
49
366
1.39
1.29
8.5
9.6
13.72
12.24
kpa
0.87
49
356
49
366
1.39
1.29
8.5
9.6
5.14
5.16
kpa
0.06
49
355
48
358
1.40
1.27
2.3
2.8
2.00
1.90
%
0.22
38
324
8
35
2.32
1.27
4.1
3.3
0.75
0.78
nmol/l
—
8
30
39
280
1.44
1.27
4.8
5.3
0.00
0.08
%
—
9
65
75
601
1.32
1.26
1.7
1.7
451.05
22674871.43
pmol/l
0.50
56
516
111
938
1.27
1.25
4.5
3.9
0.00
0.00
estimate
-0.00
48
324
108
912
1.27
1.22
3.4
2.8
—
—
—
0
0
8
37
2.19
1.22
1.4
1.3
—
—
—
0
0
36
257
1.45
1.22
4.8
3.5
—
—
—
0
0
21
133
1.62
1.20
4.6
8.2
2.03
1.54
%
0.76
21
124
12
64
1.91
1.19
2.7
4.1
—
—
—
0
0
6
26
2.33
1.19
2.0
2.0
—
—
—
0
0
97
812
1.27
1.17
3.1
2.9
373.11
343.56
umol/l
1.90
87
725
117
1003
1.25
1.16
4.3
3.5
25.35
56.59
mg/l
3.07
73
646
119
1023
1.25
1.15
5.3
4.1
3.40
9.82
mg/mmol
4.42
75
633
125
1084
1.24
1.11
4.1
3.3
7.39
7.87
mmol/l
0.61
105
917
144
1271
1.23
1.08
4.5
3.6
0.05
0.01
estimate
0.40
42
287
300
2867
1.34
1.07
4.7
4.2
1.37
1.27
mmol/l
1.57
278
2652
10
52
1.95
1.07
2.3
2.8
—
—
—
0
0
12
67
1.82
1.06
1.3
1.3
—
—
—
0
0
24
163
1.51
1.05
1.7
1.5
0.47
0.31
mg/l
—
10
67
312
3002
1.38
1.04
5.6
5.0
1.40
1.47
mmol/l
2.03
291
2794
7
34
2.08
1.03
1.0
1.3
—
—
—
0
0
53
417
1.32
1.03
2.1
3.3
4.28
5.61
e9/l
0.76
41
373
35
259
1.39
1.00
1.9
2.7
0.14
0.19
e6/l
0.34
35
247
37
279
1.36
0.95
3.9
4.3
7.39
7.33
ph
2.33
32
207
91
777
1.23
0.92
1.4
1.3
0.56
1.46
u/ml
1.83
22
204
6
28
2.16
0.92
2.5
2.4
—
—
—
0
0
50
398
1.30
0.90
1.2
1.4
—
—
—
0
0
31
229
1.39
0.90
1.4
1.2
—
—
—
0
0
6
29
2.09
0.89
1.0
1.3
0.37
1.27
promille
—
6
22
312
3015
1.34
0.88
5.7
5.1
4.60
4.64
mmol/l
0.35
296
2826
8
43
1.88
0.88
1.9
3.3
—
—
—
0
0
8
43
1.88
0.88
1.1
2.5
—
—
—
0
0
35
267
1.35
0.85
1.2
1.2
—
—
—
0
0
6
31
1.95
0.85
1.2
1.1
—
—
—
0
0
6
32
1.89
0.82
1.8
1.4
—
—
—
0
0
40
316
1.30
0.78
1.7
1.5
—
—
—
0
0
6
34
1.78
0.76
4.3
3.9
2.35
2.90
nmol/l
—
6
34
12
75
1.62
0.76
2.9
3.0
56.67
59.41
%
0.29
12
75
5
24
2.10
0.75
1.4
3.9
287.60
1035.67
mg
—
5
24
6
106
0.56
0.73
5.0
9.6
—
—
—
0
0
5
25
2.01
0.73
1.2
1.7
—
—
—
0
0
7
39
1.81
0.73
1.0
1.2
—
—
—
0
0
45
365
1.27
0.72
1.8
1.8
—
—
—
0
0
314
3052
1.30
0.71
6.5
5.7
2.75
2.73
mmol/l
0.20
294
2852
5
27
1.86
0.68
1.6
1.1
—
—
—
0
0
5
92
0.54
0.68
1.4
1.4
—
—
—
0
0
102
907
1.18
0.67
1.8
1.7
20.09
20.53
nmol/l
0.11
90
774
73
632
1.20
0.65
1.3
1.3
17.60
31.06
iu/ml
1.02
14
193
18
129
1.42
0.65
2.3
1.9
2.57
4.39
ug/l
0.30
13
114
36
289
1.27
0.64
2.3
2.1
0.60
0.00
estimate
—
5
61
51
428
1.22
0.62
2.0
2.4
89.57
128.30
ug/g
0.78
43
339
34
272
1.28
0.62
1.9
2.4
10.83
13.42
nmol/l
0.96
27
252
8
53
1.52
0.59
1.4
1.2
—
—
—
0
0
8
53
1.52
0.59
5.7
3.1
7.37
9.63
pmol/l
—
8
53
35
284
1.26
0.58
1.6
1.5
—
—
—
0
0
23
176
1.33
0.58
1.2
1.1
—
—
—
0
0
6
36
1.68
0.57
1.0
1.9
90.37
89.97
%
—
6
36
10
65
1.55
0.56
1.0
1.1
—
—
—
0
0
10
65
1.55
0.56
1.0
1.1
—
—
—
0
0
10
145
0.68
0.51
1.2
1.7
—
—
—
0
0
7
45
1.57
0.49
1.7
1.1
—
—
—
0
0
13
94
1.40
0.46
3.3
1.9
—
—
—
0
0
23
183
1.28
0.46
1.4
1.6
819.70
974.44
mu/l
0.62
18
153
14
105
1.35
0.41
3.9
2.7
—
—
—
0
0
79
716
1.13
0.41
1.9
1.4
2.83
2.40
g/l
0.45
51
441
15
115
1.32
0.39
1.5
1.5
351.21
257.66
miu/ml
—
6
57
9
66
1.37
0.38
1.1
1.0
—
—
—
0
0
262
2544
1.12
0.38
26.4
20.3
332.47
332.40
g/l
0.04
262
2535
12
89
1.36
0.38
1.1
1.2
—
—
—
0
0
16
125
1.29
0.37
1.4
1.2
—
3.35
—
0
8
14
108
1.31
0.36
1.6
1.1
0.89
0.91
g/l
0.12
14
108
6
43
1.40
0.35
1.2
1.2
—
—
—
0
0
13
100
1.31
0.34
1.5
1.1
0.50
0.73
ratio
—
5
15
6
87
0.68
0.33
1.8
2.0
119.50
220.96
pmol/l
—
6
81
87
805
1.11
0.33
2.7
2.1
2.52
2.86
mg/l
1.08
74
697
7
54
1.30
0.30
1.3
1.3
—
—
—
0
0
14
111
1.27
0.30
1.3
1.2
6.63
8.92
u/l
—
8
88
22
260
0.84
0.30
4.1
2.1
6.00
6.08
ph
0.14
13
170
34
298
1.16
0.29
5.6
4.1
7.39
7.38
ph
0.34
18
170
7
56
1.26
0.29
4.7
14.6
103.29
105.12
mmol/l
—
7
50
7
56
1.26
0.29
4.7
14.6
9.57
10.90
mmol/l
—
7
50
64
588
1.11
0.28
1.3
1.3
13.94
8.02
u/ml
0.28
24
223
8
63
1.28
0.28
2.0
1.6
—
—
—
0
0
8
65
1.24
0.27
1.3
1.7
—
—
—
0
0
14
113
1.25
0.27
1.4
1.3
—
—
—
0
0
8
66
1.22
0.27
1.4
1.3
—
—
—
0
0
9
73
1.24
0.25
1.1
1.1
—
—
—
0
0
11
87
1.27
0.24
1.2
1.6
—
—
—
0
0
5
38
1.32
0.23
1.4
2.8
1.21
1.20
mmol/l
—
5
38
5
38
1.32
0.23
1.4
2.8
108.00
105.58
mmol/l
—
5
38
5
38
1.32
0.23
1.4
2.8
4.16
4.07
mmol/l
—
5
38
5
39
1.29
0.23
2.2
2.1
—
—
—
0
0
13
107
1.22
0.22
1.5
1.1
1.58
1.55
g/l
0.24
13
107
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
5.6
—
7.83
—
0
10
0
12
0.00
0.21
0.0
1.0
—
1635.08
—
0
12
11
89
1.24
0.21
1.4
1.7
—
—
—
0
0
21
183
1.16
0.20
7.1
9.4
26.02
24.79
mmol/l
0.66
21
175
16
136
1.18
0.20
2.2
1.9
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
10
81
1.24
0.19
8.8
11.8
1.12
1.28
mmol/l
—
10
69
15
128
1.18
0.18
1.3
1.6
—
—
—
0
0
15
129
1.17
0.17
2.9
2.3
350.35
5464.24
u/l
—
6
48
15
130
1.16
0.16
1.3
1.6
—
—
—
0
0
15
130
1.16
0.16
1.3
1.6
—
—
—
0
0
9
78
1.16
0.15
3.1
3.4
40.11
35.51
umol/l
—
9
69
99
954
1.05
0.14
5.8
5.1
1.71
2.12
ug/l
0.65
86
859
78
748
1.06
0.13
4.5
3.7
1.02
1.02
kg/l
0.17
53
494
14
123
1.14
0.12
1.3
1.7
—
—
—
0
0
19
175
1.09
0.08
2.6
2.5
0.73
0.61
%
0.72
19
175
16
174
0.92
0.07
3.7
7.0
—
—
—
0
0
14
153
0.91
0.07
5.4
3.1
1.02
1.02
ratio
0.15
14
145
37
354
1.05
0.07
1.8
1.5
—
—
—
0
0
19
177
1.08
0.06
2.9
2.6
1.44
1.29
%
0.24
19
177
126
1269
0.99
0.01
3.7
3.1
—
—
—
0
0
11
104
1.06
0.01
1.2
1.3
—
2.52
—
0
16
13
131
0.99
0.00
1.3
1.6
—
—
—
0
0
26
261
1.00
0.00
1.7
1.9
3.31
3.52
mmol/l
0.47
21
200
13
133
0.98
0.00
1.0
1.1
—
—
—
0
0
12
117
1.03
0.00
1.4
2.0
45.00
41.47
nmol/l
0.27
12
111
57
574
0.99
0.00
3.2
3.1
0.75
0.76
ug/l
0.03
38
353
0
8
0.00
-0.00
0.0
2.1
—
16.41
—
0
8
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
79
1.01
-0.00
7.5
4.3
—
—
—
0
0
6
63
0.95
-0.00
3.3
4.4
18.33
26.27
mg/l
—
6
44
0
6
0.00
-0.00
0.0
2.5
—
9139.17
—
0
6
6
60
1.00
-0.00
2.7
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.8
—
54.06
—
0
9
0
9
0.00
-0.00
0.0
2.3
—
2.56
—
0
9
0
7
0.00
-0.00
0.0
1.1
—
12.80
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
35.57
—
0
7
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_OROPHA_OTHER and mortality.

Females

Parameter HR [95% CI] p-value
CD2_BENIGN_OROPHA_OTHER 1.256 [0.99, 1.6] 0.063
Birth year 0.996 [0.99, 1.01] 0.452

During the follow-up period (1.1.1998 — 31.12.2019), 117 out of 834 females with CD2_BENIGN_OROPHA_OTHER died.

Males

Parameter HR [95% CI] p-value
CD2_BENIGN_OROPHA_OTHER 1.677 [1.28, 2.2] < 0.001
Birth year 0.986 [0.98, 1.0] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 137 out of 733 males with CD2_BENIGN_OROPHA_OTHER died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_OROPHA_OTHER.

N-year risk Females Males
1 0.14% 0.328%
5 0.857% 1.893%
10 2.044% 4.924%
15 3.593% 9.149%
20 6.503% 14.734%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_OROPHA_OTHER – Benign neoplasm: Other parts of oropharynx

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data